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ABSTRACT 
Metabolic syndrome (MetS) is a clustering of risk factors for cardiovascular disease 
(CVD) and type 2 diabetes (T2D) – two major causes of morbidity and mortality 
worldwide.  Heart rate variability (HRV) is a non-invasive measure of cardiac 
autonomic regulation that predicts mortality and morbidity.  Additionally, HRV is 
reduced in CVD, T2D and MetS.  As such, HRV has potential to be a novel 
cardiometabolic risk factor to be included in clinical risk assessment.  Therefore, the 
purpose of this thesis was to examine the relationships between MetS and HRV.  A 
systematic review of cross-sectional studies examining relationships between HRV and 
MetS was completed to consolidate existing evidence and to guide future studies.  This 
was followed by a cross-sectional investigation of time and frequency domain and 
nonlinear HRV in a population with MetS risk factors to determine which MetS risk 
factors were associated with HRV parameters.  A pilot study was then conducted to 
study the feasibility of conducting a mobile health (mHealth) and exercise intervention 
in a rural population, which was followed by a 24-week randomized clinical trial to 
examine the effects of the interactive mHealth exercise intervention compared to 
standard of care exercise in participants with MetS risk factors.  Overall, HRV was 
reduced in women with MetS compared to those without, though there were no 
differences in men.  Waist circumference and lipid profiles were most commonly related 
to HRV parameters when studied cross-sectionally.  The changes in waist circumference 
and fasting plasma glucose were associated with the change in HRV parameters when 
studied longitudinally.  Following the intervention period, waist circumference and 
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blood pressure were improved with no other changes in MetS risk factors.  HRV 
parameters indicative of vagal activity were reduced over the intervention period, but 
there were no changes in other HRV parameters.  There were no differences in changes 
between the intervention and control groups.  In conclusion, MetS and HRV are 
associated in women but not men.  However, there were no clear associations between 
MetS and HRV to suggest that HRV would be a valuable clinical risk indicator.  
 
Keywords: 
Heart rate variability; autonomic nervous system; metabolic syndrome; mobile health; 
physical activity prescription; cardiovascular risk. 
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CHAPTER 1  
Review of the Literature 
1.1 Burden of Cardiovascular Disease and Type 2 Diabetes 
Cardiovascular diseases (CVD) are the leading cause of death world-wide accounting for 
48% of mortality from non-communicable diseases [1].  Additionally, CVDs are 
responsible for a significant proportion of morbidity accounting for 10% of global disease 
burden [1].  The Public Health Agency of Canada estimated the cost of CVD in Canada 
as $22.2 billion in 2000, with $7.6 billion in direct health care costs and $14.6 billion in 
indirect costs, including lost economic productivity [2].   
Type 2 diabetes mellitus (T2D) is an independent risk factor for CVD and cardiovascular 
complications are common in this patient population.  Complications range from 
microvascular disease including retinopathy to macrovascular disease including coronary 
heart disease and stroke.  In 2004, heart disease was responsible for 68% and stroke was 
responsible for 16% of all deaths in patients diagnosed with T2D in the United States [3].  
In 2009, annual diabetes-related spending was $113 billion in the United States, and this 
is expected to increase to $336 billion in 2034 [4].  With an increasingly aging and 
overweight population, the incidence and thus costs associated with CVD and T2D are 
expected to increase.  Strategies for cost effective management of cardiovascular risk 
factors to prevent or delay disease progression and reduce disease burden are needed. 
1.2  Cardiometabolic Risk 
The Canadian Cardiometabolic Risk Working Group defines cardiometabolic risk as any 
factor that increases the risk of cardiovascular morbidity and mortality [5].  Three 
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primary categories of cardiometabolic risk are: 1) Global cardiometabolic risk, which 
encompasses all novel and emerging risk factors along with the traditional factors; 2) 
Metabolic syndrome (MetS), which is a specific set of risk factors that, in combination 
increase the relative risk of developing CVD and T2D; and 3) Traditional risk scores, 
such as the Framingham Risk Score, which use validated mathematical algorithms to 
calculate an absolute cardiovascular risk [5].  The following section will discuss what 
MetS is and how it can be used in combination with absolute risk scores to classify risk.  
Importantly, heart rate variability (HRV) will be discussed including methodological 
details, physiological background, and potential as an emerging, novel cardiometabolic 
risk factor.  
1.2.1 Metabolic Syndrome 
Cardiovascular risk factors tend to cluster in a given individual.  In 1988, Reaven 
described what he termed “Syndrome X” – a combination of insulin resistance, 
hyperglycaemia, hypertension, reduced high density lipoprotein cholesterol (HDL) and 
increased low density lipoprotein cholesterol (LDL) [6].  The importance of considering 
the increased risk of developing CVD and T2D in individuals with clustering of these risk 
factors was recognized.  Since that time, Syndrome X has been re-named MetS, and the 
risk factors have been modified.  There are a number of MetS definitions, all with slightly 
different criteria.  The National Cholesterol Education Program – Adult Treatment Panel 
III (ATPIII) guidelines are most widely used criteria as they are more focused on all-
round CVD risk.  Diagnosis requires the presence of three of the following five risk 
factors in an individual: increased waist circumference (WC), blood pressure (BP), 
fasting plasma glucose (FPG) and triglycerides (TG) and reduced HDL, all of which are 
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readily measured in clinic settings [7].  MetS increases the five-year risk of developing 
CVD two-fold, and the lifetime risk of developing T2D five-fold [8]. 
The Canadian Cardiometabolic Risk Working Group emphasizes that MetS is a relative 
risk indicator and therefore, its importance will vary based on absolute cardiovascular 
risk [5].  They suggest that consideration of MetS status along with an absolute risk score 
may be ideal for clinical risk profiling.  As a relative risk indicator, the presence of MetS 
would approximately double an absolute cardiovascular risk score.  For example, an 
individual with a Framingham Risk Score of 2% with MetS would only have a combined 
ten year risk of developing CVD of 4%, while an individual with a Framingham Risk 
Score of 20% with MetS could be considered to have an actual risk of 40% [5].  
Longitudinal studies are needed to determine the precise algorithm for the relative risk 
calculation, but the hypothetical scenario presented by the working group demonstrates 
that MetS may be particularly dangerous to individuals with high absolute risk scores.   
1.2.2 Heart Rate Variability 
Control of the heart is complex with input from many systems, including the nervous 
system.  The autonomic nervous system has two main branches: 1) The parasympathetic 
nervous system, which is responsible for slowing heart rate (HR) and reducing 
myocardial contractility; and 2) The sympathetic nervous system, which speeds HR and 
increases myocardial contractility.  Proper cardiac control is reliant on the proper 
function of and balance between these two branches of the autonomic nervous system.  
Heart rate variability (HRV) is a non-invasive indicator of cardiac autonomic function 
with important prognostic value.  Measurement involves collection of consecutive R-R 
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intervals (RRI) from an electrocardiogram (ECG) or HR monitor.  Commonly, either 
long-term recordings of 24 hours or short-term recordings of five minutes duration are 
analysed.  Since overall variability is dependent upon the length of the recording, HRV 
should only be compared within or between individuals if the same length of data was 
analysed [9].   It is necessary to remove non-sinus rhythm beats, such as premature 
ventricular contractions, before analysis.  A number of different mathematical analyses 
may be carried out to calculate HRV.   
Time domain analysis 
Time domain analysis is commonly used due to the relative ease of calculation and 
because stationary data is not required.  Therefore, it can be used to analyse 24 hour data.  
Primary time domain indices are the standard deviation of normal-to-normal intervals 
(SDNN), root mean square of successive differences (RMSSD) and the percentage of 
normal-to-normal intervals greater than 50 ms (pNN50).  Administration of low-dose 
scopolamine to enhance parasympathetic cardiac outflow increased SDNN 23%, RMSSD 
49% and pNN50 78%, suggesting significant contribution of vagal activity to each HRV 
parameter, and substantial contribution to RMSSD and pNN50 [10].  SDNN is an index 
of total cardiac variability over the recording period, while RMSSD and pNN50 measure 
short-term variation and are reflective of parasympathetically mediated processes [9].  
However, RMSSD is used preferentially over pNN50, as the mathematical algorithm is 
more robust [9]. 
Frequency domain analysis 
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Frequency domain analysis has been used extensively in research.  The RRI time series is 
decomposed into underlying frequencies using Fast Fourier Transform or Autoregressive 
modeling.  Each frequency band is classically considered to represent physiological 
processes, though there is much debate around this issue.  Signal stationarity is essential 
for valid calculation, so short-term recordings are most applicable, though data can be 
separated into equal length epochs (i.e. one hour) and averaged for the 24-hour collection 
period.  The power spectrum is composed of four power frequency bands: ultra low 
(ULF; 0-0.003Hz), very low (VLF; 0.003-0.04Hz), low (LF; 0.04-0.15Hz) and high 
frequency power (HF; 0.15-0.4Hz).  Total power (TP) is often calculated as well, as are 
both LF and HF in normalized units [LFnu = LF/(LF+HF); HFnu = HF/(LF+HF)] and 
LF/HF. 
The physiological backgrounds of the ULF and VLF bands are not as well studied as 
other measures.  Serrador and colleagues [11] showed that ULF was reduced during an 
approximately three-hour session of inactivity (i.e. sitting and reading) compared to a day 
of typical daily activity (i.e. activities of daily living, not exercise).  Since ULF was 
strongly correlated to the quantity of muscle activity, authors suggested that ULF may be 
related to mechanisms associated with modulation of energy expenditure [11].  
Generally, ULF is interpreted to be reflective of thermoregulation or hormonal systems.  
Bernardi and researchers [12] showed that rhythmic or spontaneous physical activity 
increased VLF power three- to five-fold compared to rest, suggesting that some aspects 
of energy expenditure may be represented in VLF as well.  There is also evidence to 
support some contribution of the renin-angiotensin system to VLF power, but enalaprilat 
administration to block angiotensin converting enzyme only modestly increased VLF 
6 
 
power by 21% [13].  However, atropine administration to abolish vagal outflow reduced 
VLF power 92% in healthy young adults, suggesting parasympathetic influence is the 
primary physiological component of the VLF band [13]. 
Early studies concluded that LF was an index of sympathetic activity [14], but many 
studies since have proved otherwise.  Cardiac noradrenaline spillover, the gold standard 
measurement of cardiac sympathetic outflow, was not correlated with LF power [15,16] 
and cardiac β-adrenergic stimulation decreased LF, rather than increased as would be 
expected [17].  Additionally, in conditions known to increase sympathetic outflow, such 
as congestive heart failure [18,19] and aging [20,21], LF is decreased.  In fact, age is the 
major determinant of LF oscillations at rest, with reduced LF associated with advancing 
age [22].  Additionally, in patients with pulmonary hypertension, LF power is negatively 
associated with muscle sympathetic nerve activity [23].  Exercise is a powerful 
sympathetic stimulation and LF was decreased during a bout of incremental exercise 
[24].  On the other hand, LF was reduced in response to atropine, a cholinergic blockade, 
suggesting parasympathetic influence [13].  There is some evidence to support an 
association between LF power of HRV and baroreflex function – one of the reflex control 
mechanisms for autonomic cardiac modulation.  LF power and baroreflex sensitivity 
were positively correlated [16,25] and LF was increased in participants with normal 
baroreflex function in response to baroreflex stimulation, but not in those with impaired 
baroreflex sensitivity [26].  These findings provide a basis for future investigations, but 
are not conclusive.  To date, the physiological meaning of the LF power band of HRV 
remains controversial. 
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Resting HF is classically considered to be mediated by respiratory sinus arrhythmia when 
breathing is greater than 0.15Hz, or about nine breaths per minute [9].  HF is often 
thought to quantify vagal tone since HF power of HRV is nearly completely abolished by 
parasympathetic blockade with atropine [27,28] or glycopyrolate [29,30].  However, an 
important distinction is that HF actually reflects the modulation of vagal tone, rather than 
the tonic level per se [31].  HF was reduced following both a parasympathetic blockade 
with atropine and parasympathetic withdrawal with nitroprusside; despite similar levels 
of absolute parasympathetic tone in both conditions, HF was lower during the 
parasympathetic blockade than during parasympathetic withdrawal [31].  Similarly, 
incremental doses of vagotonic atropine to increase parasympathetic tone were not 
correlated to HF or other HRV indices [32].  Research supports modulation of vagal tone 
as the primary underlying physiological process represented by the HF band.  
Nonlinear analysis 
Nonlinear analyses differ from time and frequency domain analysis as rather than 
quantifying the amount of variability they examine heart rate qualities such as fractal 
characteristics and complexity.  Detrended fluctuation analysis quantifies the fractal-like 
properties of the tachogram [33].  RRI fluctuations are calculated in windows and a log-
log curve is plotted.  The slope of the first arm of the curve defines the short-term scaling 
exponent (α1: from 4-11 beats).  When α1 is equal to one, RRI fluctuations are exhibiting 
fractal-like behaviour [34,35].  Fractal breakdown can occur with either excessive order 
(α1 = 1.5) or uncorrelated randomness (α1 = 0.5) [34].  Pharmacologic vagal blockade 
with glycopyrolate increased α1 from a value indicative of fractal like behaviour towards 
uniformity [36].  In response to physiological stimuli, α1 was increased with exercise, 
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head up tilt greater than 20 degrees [37] and cold hand immersion [35], all of which 
reciprocally increase sympathetic and reduce parasympathetic activity.  Cold face 
immersion, which co-activates sympathetic and parasympathetic outflow, resulted in 
breakdown of fractal-like behaviour demonstrated by increased α1 in all subjects [35].  In 
contrast to these studies, Tan and associates [38] reported no changes in α1 following 
total autonomic blockade or during tilt.  However, baseline values of α1 were lower in 
this study than others and authors reported that participants did not demonstrate fractal 
patterns at rest.  This group also showed that α1 was not reproducible within individuals 
[38].  Thus, the physiological background of α1 remains unclear.  Considering solely 
autonomic function may be too simplistic as fractal behaviour likely results from the 
complex interplay of all mechanisms of cardiac control. 
Poincaré Plots 
Poincaré plots are often considered nonlinear since the visual appearance of the 
scattergrams may be interpreted, but statistical algorithms can also be applied to quantify 
plots.  To construct the Poincaré plot, each RRI is plotted against the preceding RRI.  The 
width (SD1) and length (SD2) of the scattergram can be calculated.  SD1 was reduced 
with atropine and increased with scopolamine [39] and is considered a measure of short-
term variability, primarily of parasympathetic origin, while SD2 is a measure of total 
variability [40,41].  Since stationarity is not required, SD1 may be used in place of HF to 
quantify the vagal component during a dynamic stimulus, such as exercise. 
Summary of the physiological background of heart rate variability 
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In summary, modulation of the parasympathetic outflow, rather than parasympathetic 
tone, appears to be the main contributor to time and frequency domain and Poincaré plot 
parameters.  The physiologic mechanisms related to nonlinear HR dynamics remain 
debatable, as do specific mechanisms associated with the lower frequency power bands.  
Since HRV represents complex physiological interactions, it is difficult to isolate specific 
mechanisms.  Physiological manoeuvres, such as tilt, to stimulate autonomic nervous 
responses also affect hormonal and other body systems.  Likewise, pharmacological 
agents to stimulate or block autonomic processes may have unintended systemic or local 
effects that may alter HRV.   
Although there are a number of limitations associated with HRV data processing and 
interpretation, it is used extensively in research and it has been suggested as a valuable 
clinical tool.  Since it is non-invasive and RRIs are easily collected, HRV is a useful tool 
for examining autonomic function in large population studies.  These characteristics give 
HRV the potential to be a useful clinical tool as a novel cardiometabolic risk indicator.  
The following section explores this potential in greater detail by discussing the prognostic 
value of HRV. 
Predictive value of heart rate variability 
A landmark study showed that post-myocardial infarction patients with reduced HRV 
(24h SDNN < 50 ms) had triple the risk of all-cause mortality compared to those with 
higher SDNN [42].  Similarly, post-myocardial infarction patients with 24h SDNN < 70 
ms had a 2-year mortality of 10% compared to 2% in patients with normal SDNN [43].  
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Reduced ULF and VLF components of frequency domain analysis have been linked to 
patient prognosis following myocardial infarction [44-46].   
Research has also examined the prognostic value of short-term HRV in general 
populations.  It has been reported that over a mean follow-up of 9.2 years, those who died 
had impaired autonomic function demonstrated by reduced SDNN, LF and HF, though 
there were no differences in LF/HF [47].  Importantly, HRV is reduced in T2D [48,49], a 
population with a high risk of CVD.  Furthermore, those presenting with autonomic 
impairment and T2D had approximately double the risk of mortality compared to those 
with autonomic impairment, but without T2D [47].  These studies suggest an interactive 
effect between traditional cardiovascular risk factors and autonomic function. 
A number of studies have examined associations between MetS or its component risk 
factors and HRV [50-64].  Generally, HRV is reduced in MetS compared to healthy 
populations and some MetS risk factors were associated with HRV parameters.  
However, these associations vary considerably based on the study population.  A critical 
examination and review of these findings is needed to synthesize results. 
More work is needed in this area to determine specific HRV thresholds for CV risk, as to 
date, they have been arbitrarily determined based on quartiles.  Assuming HRV 
parameters reflect different physiological processes, alteration of specific HRV 
parameters may indicate risk for specific disease processes.  Despite the need for more 
knowledge of the physiological background of HRV parameters, evidence to date 
supports the prognostic value of HRV, suggesting it may be a useful global 
cardiometabolic risk factor to be considered in risk profiles. 
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1.3 Risk Management 
An Archimedes model of the United States population showed that 78% of adults were 
candidates for CVD prevention activities, including aspirin administration, weight 
reduction and control of BP, FPG and lipids [65].  If everyone took part in the prevention 
activities for which they were candidates, incidence of myocardial infarction and stroke 
would be reduced by 63% and 31%, respectively [65].  Even when more feasible 
participation levels were considered, myocardial infarction and stroke could be reduced 
36% and 20%, respectively [65].  However, with the current modes of intervention 
delivery, the only cost-effective prevention activity was smoking cessation [65].  Thus, 
strategies are needed to develop cost-effective prevention programs targeting other 
important risk factors. 
Insufficient physical activity is the fourth leading risk factor for cardiovascular mortality, 
behind raised BP, tobacco use and raised FPG [1].  According to accelerometer data 85% 
of Canadians [66] and 90% of Americans [67] are not meeting recommended physical 
activity guidelines.  Greater cardiorespiratory fitness has been shown to provide a strong 
protective effect, attenuating the effects of MetS on all-cause and cardiovascular 
mortality in men [68].  Thus strategies for delivery of cost-effective interventions for 
increased physical activity, especially those aimed at increasing cardiorespiratory fitness, 
have the potential to substantially reduce CVD burden.  The next section discusses the 
efficacy of exercise training as a cardiometabolic risk modifier by examining effects on 
MetS and HRV. 
1.3.1 Exercise interventions in Metabolic Syndrome 
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Health behaviour modification, including increased physical activity to meet global 
guidelines [69], is recommended as a primary treatment strategy for cardiometabolic risk 
[5,8].  The effects of exercise on individual MetS risk factors have been reviewed 
extensively [5,70,71].  However, only one meta-analysis has examined the effects of 
exercise on MetS risk factors in studies on populations with MetS [72].  Of the studies 
included in the meta-analysis, training interventions were eight to 52 weeks duration, 
frequency of two to five sessions per week for 40-60 minutes per session at moderate to 
high intensity, with the exception of one study which examined low intensity exercise.  
Endurance exercise training reduced WC, SBP and DBP and increased HDL, with no 
changes in FPG or TG [72].  Authors suggested that the reduction in FPG may have 
reached statistical significance had baseline values been higher, but since only one study 
included individuals with T2D, FPG was relatively normal prior to exercise training [72].  
High intensity interval training resulted in greater improvements in FPG than moderate 
intensity continuous exercise of the same volume, while changes in WC and BP were 
similar between groups [73].  Since few studies included in the systematic review 
included high intensity exercise, this may also explain lack of change in FPG.  However, 
with low levels of participation in physical activity, moderate intensities may be more 
acceptable for the general population and therefore more likely to be adopted into daily 
habits than vigorous activity.   
The Diabetes Prevention Study and Diabetes Prevention Program were two landmark 
studies investigating the effects of lifestyle intervention on disease progression.  The 
Diabetes Prevention Study compared a lifestyle intervention aimed at increasing physical 
activity and dietary fibre and reducing saturated fats with a 5% weight loss goal to a 
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control group [74].  Participants were aged 40-65y, overweight and presented with 
impaired glucose tolerance [74].  After a mean study duration of 3.2y, MetS risk factors 
WC, SBP, DBP, FPG and TG were reduced to a greater extent in the intervention 
compared to the control group, with no differences in HDL.  Additionally, after two 
years, the risk of developing type 2 diabetes was 58% lower in the intervention than the 
control group [74].  At four [75] and nine [76] years following cessation of the 
intervention, relative risk remained 43% and 38% lower, respectively in the intervention 
group.  Risk reduction was predicted by adherence to the lifestyle changes after the 
program had stopped [75,76], highlighting the importance of post-program support.   
The Diabetes Prevention Program similarly compared an intensive lifestyle intervention, 
but to pharmacological therapy with metformin or placebo plus standard lifestyle 
recommendations [77].  Participants were aged 25y and up, overweight and had impaired 
glucose tolerance [77]. At an average follow-up of 2.8y, incident diabetes was reduced by 
31% in the metformin group and 58% in the intensive lifestyle intervention group 
compared to the placebo group [77].  Following this intervention, all participants were 
invited back for a long-term follow-up with the intensive lifestyle intervention and after 
ten years, the incidence of diabetes was equal in all groups, now receiving equal lifestyle 
advice and support [78].  This is supported by a recent meta-analysis which demonstrated 
the effectiveness of both pharmacological and lifestyle interventions in reversing MetS 
[79].  When MetS was treated with anti-diabetic, lipid controlling or appetite suppressant 
pharmacotherapy, the odds of MetS reversal was increased 60% compared to control with 
no intervention, and when MetS was treated with lifestyle intervention (dietary or 
exercise advice or supervised exercise), the odds of MetS reversal was increased almost 
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four-fold compared to control [79].  Although the heterogeneity of studies included in the 
analysis prevented conclusive results, there was an 87% probability that lifestyle 
interventions were more effective than pharmacological interventions [79].  Together, 
these studies highlight the importance of lifestyle interventions, including physical 
activity, to treat MetS risk factors and importantly to prevent development of disease.   
1.3.2 Exercise interventions to improve HRV 
Studies investigating the effect of exercise on HRV have had mixed results.  An early 
study showed that young adults with mild hypertension who completed 22 minutes of 
calisthenics followed by 20 minutes of jogging a minimum of five times per week 
increased resting RRI and HFnu and reduced LFnu [80].  A 30-week exercise training 
intervention, walking or jogging three to four times per week for 30 minutes per day at 
68-81% HR reserve increased SDNN in middle-aged to older men [81].  Similarly, in 
post-menopausal women, lower intensity exercise at 50% of maximal oxygen uptake 
(VO2max) three to four times per week for 45 minutes increased RMSSD, SDNN and 
absolute values of frequency domain HRV parameters, with no change in LFnu or HFnu 
[82]. One study in T2D patients with and without cardiac autonomic neuropathy showed 
improvement in HRV parameters following six months of aerobic exercise three times 
per week at 70-85% of HR reserve [83]. Other studies also showed improvements in 
HRV in sedentary men following eight weeks of exercise training 6 days per week for 
30-60 minutes per session [84,85], and these improvements were partially preserved 
following 10 months of post-program home-based exercise [84].  Conversely, one study 
showed no change in HRV parameters at rest or during exercise in older men and women 
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after eight weeks of aerobic exercise training three times per week for 60 minutes each 
session [86].   
Other studies found that while resting HRV was not altered with endurance training, 
HRV was altered during exposure to stressors [87-89].  One session of high-intensity 
training and one session of low-to-moderate intensity exercise per week for 14 weeks 
reduced HR and increased HRV at the same absolute workload following training, but 
there were no differences in resting HRV, or HRV at the same relative workload [88].  
Similarly, in obese women with and without T2D, 16 weeks of moderate intensity 
endurance training (65%VO2max) four days per week increased post-exercise HR 
recovery, HF and LF with no changes in resting HRV [87].  Six months of exercise 
training two days per week for 70 minutes at moderate intensity did not affect resting 
HRV in T2D patients, but HFnu was increased and LF/HF reduced during an orthostatic 
challenge [89].  Reasons for discrepancies between trials may be due to exercise program 
or population characteristics. 
Frequency of exercise training may be an important factor, as those with sessions five to 
six times per week [80,84,85] showed improved HRV, while in those with training 
sessions four times per week or less, results were mixed.  In four studies that did not 
show changes in resting autonomic function, exercise training frequency was only two or 
three times per week  or only one session per week was supervised and the remaining 
were completed at home, so compliance to the exercise protocol may not be as high as 
reported.   
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Exercise duration, on the other hand, did not affect HRV modifications toward vagal 
dominance following an eight-week aerobic exercise intervention [85].  Thirty or 60-
minute sessions six times per week at approximately 75% VO2max had similar effects on 
frequency domain HRV parameters and fractal correlation properties of RRI data [85].  
Again, moderate-to-vigorous activity on most days of the week appears to be important 
for HRV modification, though duration longer than 30 minutes does not seem to have 
added value. 
Exercise intensity may play a role in modifying HRV.  Cornelissen and associates [90] 
showed that healthy adults aged 55 years and older completing three one-hour exercise 
sessions per week for ten weeks reduced RRI when intensity was both 33% and 66% of 
HR reserve.  However, only the lower intensity group increased TP, though there were no 
changes in other HRV parameters in either group [90].  However, a number of exercise 
interventions with moderate-to-vigorous intensity exercise reported change [80,81,83-
85].  Differences may be due to participant characteristics.  Overtraining has been shown 
to reduce HRV in athletes [91], so in the general population and especially in sedentary 
and patient populations HRV may be reduced at lower training loads.  Kiviniemi and 
colleagues [92,93] developed a protocol whereby daily training intensity was prescribed 
according to morning HRV.  If HRV was increased, higher intensity exercise was 
prescribed, or if HRV was reduced lower intensity exercise or a day of rest was ordered 
[92,93].  This unique protocol may produce the ideal exercise training program 
optimizing frequency and intensity based on individual physiological state.   
 Age may be important factor in HRV responses to exercise.  Lee and colleagues [94] 
examined the effects of low doses of atropine (which are parasympathomimetric, as 
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opposed to higher doses, which are parasympatholytic) on changes in RRI and HRV in 
young and old fit and unfit individuals.  While resting RRI was increased in fit 
individuals compared to unfit, the responses to parasympathomimetic atropine were 
affected by age and fitness did not attenuate age-related declines in response [94].  Thus 
the lack of change in HRV in response to exercise training may be due to reduced 
function or sensitivity of the sinus node with age, which may not be modified with 
intervention.  One study in older women showed that exercise improved HRV when 50%, 
100% or 150% of national exercise guidelines was completed; however, in women aged 
> 60y, there were no improvements at lower exercise doses – only higher ones [95].  
These findings suggest that improved HRV may be less attainable in older age groups 
and that achievement of National physical activity guidelines may be especially 
important in older populations to manage cardiometabolic risk. 
In the Diabetes Prevention Program, intensive lifestyle modification (physical activity 
and low fat diet) reduced HR and increased SDNN and RMSSD compared to metformin 
or placebo [96].  Importantly, reductions in HR and increases in SDNN and RMSSD over 
time were associated with lower risk of incident diabetes, independent of weight loss and 
physical activity in the lifestyle modification group, supporting the use of HRV or the 
change in HRV in response to an intervention, as a risk indicator [96].  HRV was 
measured from 10s ECG segments, so neither frequency domain nor nonlinear 
parameters could be examined, which also have important prognostic power, as reviewed 
earlier.  Nevertheless, these results are promising and suggest that lifestyle modifications 
are important for risk reduction in a diabetes prevention strategy.   
1.4 Strategies for exercise programming 
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There is a plethora of evidence to support exercise as an important component of 
cardiovascular risk reduction and diabetes prevention programs.  While supervised 
exercise is important in clinical studies to ensure program compliance and to properly 
control factors such as exercise intensity and duration, implementation of such programs 
at a population level would be costly and impractical.  The following section discusses 
two strategies for exercise intervention that have potential to cost-effectively reach a 
large population and effectively reduce cardiometabolic risk. 
1.4.1 Exercise Prescription in Primary Care 
Exercise prescription in primary care has proved to successfully engage patients in 
healthy physical activity behaviours [97] and receiving a written prescription is more 
effective than oral advice [98].  The Step Test and Exercise Prescription (STEP™) is an 
effective tool for testing fitness and providing a written exercise prescription in primary 
care [99] and it has been validated in adults aged 18-85 years [100,101].  The STEP™ 
fitness assessment involves stepping up and down a set of two steps (each with a rise of 
20cm) 20 times at a pace the participant would normally climb the stairs [99].  Since 
there was no difference in outcome when the test was completed at a normal or a fast 
pace, a normal pace was selected to make the test safer for a broader population [101].  
Post-exercise HR is palpated from the radial artery and included in a predictive equation 
for VO2max.  Appendix 1 provides the full STEP™ protocol including the predictive 
equation.  Following the step test, an exercise prescription is written including fitness, 
fitness rating, a target exercise HR and recommendations for aerobic exercise based on 
national guidelines. 
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Implementation of STEP™ requires few resources.  In primary care it can be delivered 
either by a physician or allied health professional, and counseling can be done 
individually or in groups. Additionally, STEP™ is also valid when a standard staircase or 
kitchen step stool is used in place of the original STEP™ unit [102].  Since few resources 
are needed, STEP™ could also be implemented in community settings to reduce the 
burden on family health teams and to reach individuals who do not have a family 
physician. 
A recent systematic review and meta-analysis showed that STEP™ was the only exercise 
prescription in primary care intervention protocol that showed significant effects on 
cardiorespiratory fitness [103], which is important considering that increased 
cardiorespiratory fitness reduced cardiovascular mortality [68].  Authors hypothesized 
that this was due to one feature that was unique to STEP™, which was the inclusion of 
prescription of a target exercise HR [103].  Global guidelines recommend accumulating 
150 minutes of moderate-to-vigorous aerobic activity weekly for optimal health benefits 
[69]; thus, inclusion of target exercise HR could be an important component to the 
exercise prescription to ensure that the appropriate exercise intensity is reached. 
STEP™ has proved to be an effective tool, particularly as a first-line treatment for MetS.  
A recent review showed that STEP™ effectively improved MetS risk factors by reducing 
WC, BP and FPG, although there were no changes in TG or HDL despite positive 
changes in total and LDL cholesterols [99].  STEP™ intervention has also improved 
more novel cardiometabolic risk factors, including carotid artery β-stiffness index, 
distensibility and strain [99].  Thus, STEP has the potential to be an important tool, either 
in the clinic or community, for cardiometabolic risk management.  Since STEP 
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interventions have consistently improved cardiorespiratory fitness and cardiometabolic 
risk factors, HRV may also be positively influenced, though this has not yet been 
examined. 
1.4.2 Mobile Health Interventions 
Electronic health (eHealth) is defined as “an emerging field in the intersection of medical 
informatics, public health and business, referring to health services and information 
delivered or enhanced through the Internet and related technologies” [104].  mHealth is a 
branch of eHealth with essentially the same goals, but with the added benefit of mobility 
and portability, since the technological medium is a mobile phone.  In the United States, 
85% of the population owns a mobile phone, and in this group smartphone ownership has 
risen from 33% in May 2011 to 53% in November 2012 [105]. With the rapid growth of 
smartphone users, mHealth interventions allow for the potential to reach a broad 
population.  Importantly, many lower income and minority groups have opted to own a 
smartphone instead of a home computer as a more cost-effective means to combine 
mobile phone and internet service [106].  In fact, world-wide, the use of short message 
service (SMS – text messaging) is approximately double that of the internet [107]. 
There are a number of potential benefits to mHealth interventions.  Firstly, as already 
mentioned, they have the potential for broad reach, since a large proportion of the 
population owns a mobile phone [105].  Secondly, much like other eHealth interventions, 
they allow for interactivity to engage users.  Interactivity is important for communication 
between users or between users and technology and it is sometimes considered necessary 
for behaviour change [108].  Thirdly, since many keep their mobile phone nearby at all 
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times, it has the potential to act as a trigger or call to action to complete a behaviour. The 
iStepLog smartphone application was developed to supplement the 10,000 Steps internet-
based program and researchers showed that participants used the smartphone application 
71.2% of the time and the website only 28.8% of the time [109].  With the opportunity to 
use either medium for intervention support, smartphone was more popular, possibly 
because of the increased convenience.  Fourth, with internet connectivity, smartphones 
can empower users by allowing the ability to search for health information when it is 
needed. 
While mHealth interventions have the potential to reach a broad population, there are 
some limitations.  First, since technology changes so quickly, it is difficult to run and 
complete robust clinical trials before new and improved applications and technologies are 
available and privacy must be ensured according to HIPPA or other governing bodies.  
Secondly, there are subgroups of the population with less access to mobile phones, and 
some of these are important groups for health interventions, such as the elderly [106].  
Lastly, additional costs to activate some features of mobile phones may prevent or limit 
the ability of some to use mHealth interventions to their fullest potential [106]. 
A recent meta-analysis of mHealth interventions to increase physical activity reported 
increased pedometer steps, but no change in moderate-to-vigorous physical activity 
duration [110].  This may be due to differences in populations, as the three studies 
included in the analysis that examined pedometer steps included adults and one of these 
was for chronic obstructive pulmonary disease rehabilitation, which may have increased 
motivation to comply to the intervention.  In contrast the studies examining changes in 
moderate-to-vigorous physical activity duration included one group of children, one of 
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teenagers, and the remaining three were of adults, including one group of post-natal 
women.  Older adults are more compliant with technology interventions [111], which 
may account for differences.  The results of the meta-analysis should be interpreted with 
caution.  Authors noted that due to the few numbers of published studies, those included 
in the analysis were rather heterogeneous [110].  Study duration ranged from two to 52 
weeks, age ranged from children to older adults, and intervention delivery varied greatly, 
despite the fact that mobile phones were used in all studies.  Additionally, most studies 
using mobile platforms did not use the full range of features and many used only SMS for 
reporting and follow-up.   
Research to date supports the use of mHealth interventions for diabetes management.  In 
a meta-analysis of 22 studies, Liang and associates [112] reported that reductions in 
glycated hemoglobin (HbA1c) were 0.5% greater in the mHealth groups compared to 
control groups, and this difference was even greater in T2D (0.8%).  Trials included in 
this meta-analysis were three to 12 months duration and the interventions using the 
mobile phone were diverse.  Most interventions included transmission of self-monitored 
FPG, though some used the mobile phone for education only.  Twelve of the trials used 
mobile phone in conjunction with internet as the medium for intervention delivery.  Two 
trials compared internet-based to mobile phone-based interventions.  One showed that 
improvements in HbA1c levels, satisfaction levels and adherence to study protocols were 
similar between groups [113], while the other showed no change in HbA1c in either 
group, but there were differences in intervention use [114].  The mobile phone-based 
group responded to more reminders to check glucose, but the internet-based group 
submitted more measurements without reminders.  Submission of measurements was 
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higher in the mobile phone group at the beginning of the intervention and decreased in 
both groups such that in the final month of a three-month intervention, only one of 
eighteen receiving email reminders and three of twenty-two receiving SMS reminders 
continued to submit measurements [114].  Together these findings suggest that while the 
overall results of mHealth versus internet-based interventions may be similar, use of 
these technologies is different.  Interventions may have greater impact if device use is 
investigated and future protocols are developed according to use patterns. 
Evidence also supports the use of mHealth technology for BP control in patients with 
T2D and uncontrolled hypertension.  Logan and colleagues [115] tested the effects of a 
one-year self-care support intervention, in which participants received a smartphone and 
Bluetooth enabled BP monitor.  Once participants submitted BP measurements, they 
received automated feedback via smartphone application.  If BP was outside of pre-
determined limits, they were prompted to take additional measurements and to schedule 
physician follow-up appointments if needed.  Compared to a control group, who 
monitored BP, but did not get feedback, the intervention group reduced daytime 
ambulatory systolic BP by 9 mmHg, while there was no change in the control group 
[115].  Importantly, all of the self-care messages were automated and neither researchers, 
nor health care workers were regularly in contact with participants throughout the trial.   
Interventions utilizing mHealth technology have shown potential as important tools for 
disease management.  To date, one pilot study has examined the effects of an eHealth 
intervention with a mHealth component in an attempt to control MetS risk factors and 
thus, prevent disease progression [116].  The study enrolled 226 workers with at least one 
MetS risk factor according to ATPIII guidelines.  The workplace eHealth program 
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consisted of a four-week education module (60 minutes per session) plus access to 
telephone counseling, SMS messages and/or email messages for six months.  
Additionally, pedometers were used to record daily step counts and BP monitors and 
body fat scales were available in “eHealth zones”, which were installed in each 
participating workplace, to measure BP twice daily and body fat once weekly.  SMS 
messages were sent once weekly to counsel regarding mean step counts, BP and body fat 
or to follow-up when BP exceeded a threshold limit of 160/100 mmHg.  Emails were sent 
monthly with a summary of readings.  Following six months, WC, SBP, DBP and TG 
were reduced, with no changes in HDL [116].  FPG was also reduced, though only in the 
group that started with MetS, not in the group with less than three MetS risk factors at 
screening [116].  Additionally, the number of risk factors was reduced at follow-up – nine 
percent of the population ended the study with zero risk factors, whereas everyone 
commenced the study with at least one.  In summary, this six-month eHealth intervention 
improved MetS risk; however, it was limited to a population of workers whose employers 
accepted the Healthy Workplace Program.  Additionally, FPG was not monitored, despite 
the relative ease of obtaining those measures.  Future research is needed to examine the 
efficacy of a mHealth intervention aimed at home monitoring and management of risk 
factors, which would allow for the inclusion of a broader population.   
1.5 Thesis overview 
The overall objective of this thesis was to examine relationships between MetS risk 
factors and HRV parameters.  This was accomplished both cross-sectionally, by 
examining associations between MetS components and HRV, and longitudinally by 
investigating associations between changes in MetS components and changes in HRV in 
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response to a novel intervention combining exercise prescription in primary care with a 
mHealth home monitoring intervention for reducing cardiovascular risk.  It was 
hypothesized that HRV parameters would be associated with MetS risk factors.  
Additionally, it was hypothesized that both MetS and HRV would be improved with a 
mHealth-supported exercise intervention and that the changes in HRV will be associated 
with changes in MetS risk factors. 
Chapter 1 has provided basic background information on HRV and MetS.  A literature 
review examining the effects of lifestyle intervention, primarily increased physical 
activity and exercise, on modification of MetS risk factors and HRV suggests that there 
may be a link between the two cardiovascular risk factors.  While exercise is known to 
improve cardiovascular risk, a large proportion of the population does not engage in 
sufficient amounts of physical activity to get full benefits.  This chapter also examined 
the potential of written exercise prescription in primary care settings or mHealth 
supported interventions for health promotion. 
Chapter 2 is a systematic review to synthesize the cross-sectional evidence to date that 
has examined differences in HRV in populations with or without MetS and/or 
associations between HRV parameters and MetS risk factors.  This study found that HRV 
was lower in women with MetS compared to those without, but that findings in men were 
mixed.  One study included in the review suggested that autonomic dysfunction may be 
the factor responsible for insulin resistance, as alterations in HRV (SDNN and α1) were 
seen in persons with one or more risk factors, while alterations in insulin resistance were 
not apparent until at least two risk factors were present [52].  The review concluded that 
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more rigorous analysis was needed in future examinations to gain greater understanding 
of potential mechanisms associated with autonomic dysfunction in MetS. 
Chapter 3 is a cross-sectional investigation of associations between HRV parameters and 
MetS risk factors.  As hypothesized, autonomic impairment (demonstrated by reduced 
HRV) was generally seen in women with MetS, but not men.  Multiple linear regression 
models were run with and without insulin resistance included to determine whether it 
strengthened the predictive model.  Insulin resistance was associated only with HR, 
which may be reflective of sympathetic activity in MetS populations.  While these 
findings suggest that insulin resistance contributes to sympathetic hyperactivity, but not 
impaired vagal function in MetS, cross-sectional studies do not allow for conclusive 
findings, and longitudinal studies are needed. 
Chapter 4 is a pilot study to test the feasibility of a mHealth intervention to increase 
physical activity and improve the cardiometabolic risk profile in a rural population.  This 
eight-week study proved that the technology was acceptable and feasible for participants 
and researchers.  Additionally, despite the short intervention period, fitness and some 
MetS risk factors were improved and HRV was modified.  However, due to the single-
sample design of the study, it cannot be concluded that the mHealth support provided any 
additional benefit to the exercise prescription. 
Chapter 5 sought to  examine longitudinal associations between changes in HRV 
parameters and MetS risk factors caused by increased physical activity.  To promote 
increased activity, a randomized controlled trial was run comparing a mHealth 
application to support increased physical activity to standard of care exercise 
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prescription.  Only changes in HR, SDNN and α1 were associated with changes in MetS 
risk factors.  
Chapter 6 summarizes the overall thesis and provides direction for future research and 
knowledge translation activities. 
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CHAPTER 2 
Heart Rate Variability and the Metabolic Syndrome – A Systematic Review 
2.1. Introduction 
 Metabolic syndrome (MetS) is a clustering of risk factors that increases the relative risk 
of developing cardiovascular diseases (CVD) and type 2 diabetes mellitus (T2D) more in 
combination than the simple addition of individual risk [1].  CVDs are the leading cause 
of mortality worldwide [2] and it has been suggested that management of MetS risk 
factors could substantially reduce risk [3].  Cardiac autonomic function, which can be 
measured non-invasively with heart rate variability (HRV), has been suggested as a 
potential mechanism underlying the development of MetS and CVD because of its 
predictive power [4].  Autonomic dysfunction characterized by reduced HRV is 
predictive of development of coronary heart disease [4,5] and T2D [6,7] and of all-cause 
and cardiac mortality [8,9].  From this perspective, HRV could be a valid tool for 
monitoring the progression of CVD. 
To gain insight into the potential relationship between autonomic function and 
development of CVD, a number of cross-sectional studies have examined relationships 
between HRV and MetS [10-23].  Studies have examined differences between HRV in 
individuals with (MetS+) or without MetS (MetS-) and have investigated associations 
between HRV parameters and individual MetS risk factors.  A number of different MetS 
definitions, data collection protocols and analyses have been used, which makes 
interpretation of results difficult.  Therefore, the purpose of this systematic review was to 
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describe the evidence in the literature examining relationships between HRV and MetS 
and to provide recommendations for future studies.   
2.2.  Methods 
2.2.1 Study Inclusion/Exclusion Criteria 
The population of interest was adults aged ≥ 18 years.  Studies were required to utilize 
one of the major MetS definitions [24-27] – therefore, the search was limited to the years 
1999 (following publication of WHO guidelines) to 2012.  Studies were included if they 
examined differences in standard HRV parameters [time domain (standard deviation of 
normal to normal RR intervals (SDNN), root square mean of successive differences 
(RMSSD); frequency domain (ultra low (ULF: 0-0.003Hz), very low (VLF: 0.003-
0.04Hz), low (LF: 0.04-0.15Hz) and high (HF: 0.15-0.4Hz) frequency and total power 
(TP)) or non-linear (Poincaré plot standard deviation of instantaneous (SD1) and 
continuous variability (SD2); detrended fluctuation analysis short-term scaling exponent 
alpha (α1); beta-index (β) and approximate entropy)] between MetS+ and MetS-, or if 
they examined associations between HRV and the overall number of MetS components 
present or between HRV and individual MetS risk factors.  Studies were limited to those 
examining humans.  Only papers published in English were included in this review.   
2.2.2 Search Strategy 
EMBASE and PubMed (1999-December 2012) databases were searched for articles with 
the key words “heart rate variability” and “metabolic syndrome”.  In press articles that 
could be accessed electronically ahead of print were searched and included in the review.  
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Reference lists of included papers were examined to select papers that were not identified 
through database searches. 
2.2.3 Quality Appraisal 
Articles were reviewed and scored with a Downs and Black scale [28] modified to be 
appropriate for the cross-sectional studies included in this review.  A maximum score of 
17 was attainable.  Data were extracted (with a form created specifically for this review) 
on sample size, population demographics, HRV analysis details, MetS classification, 
HRV in MetS+ versus MetS-, HRV associations with the number of MetS components 
and with each MetS risk factor – that is, waist circumference (WC), systolic and diastolic 
blood pressure (SBP; DBP), fasting plasma glucose (FPG), triglycerides (TG) and high 
density lipoprotein cholesterol (HDL).  Authors were contacted in an attempt to clarify 
data, when needed. 
2.3. Results 
2.3.1 Identification of Studies 
The initial search returned 72 articles.  Twenty-five were excluded  because they were 
not original journal articles (i.e. review papers, editorials, letters, notes or abstracts) and 
twelve were duplicates across databases.  Therefore, 35 abstracts were reviewed.  
Seventeen papers were excluded from the review because analysis did not examine 
associations between MetS and HRV directly (n=6), experimental design was 
longitudinal and cross-sectional analyses were not included (n=5), the population did not 
meet inclusion criteria (due to disease, age or MetS definition that was not standard) 
(n=4), or heart rate parameters other than standard measures of variability were examined 
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(n=2).  Eighteen full-text articles were reviewed.  Four papers were excluded because 
standard MetS definitions were not used (n=2), HRV analyses were not standard (n=1), 
or associations between MetS and HRV were not directly examined (n=1) (Figure 1).   
2.3.2 Summary of Included Studies 
The 14 studies included in the review are summarized in Table 2.1.  Quality scores 
ranged from 7-14 out of a maximum of 17.  Despite known sex differences and age 
effects, not all studies adjusted for these variables.  Only three studies separated analysis 
by sex [10,13,17] and three study populations included only males [11,14,15].  
Additionally, heart rate (HR) is known to affect HRV and only one study included an 
adjustment for this variable [17]. 
Most studies analysed short-term HRV over a period of three [17] or five [10-13,15,18-
20,22] minutes.  The ECG recording was collected in the supine [10-13,17,22] or seated 
position [18-20], or unspecified [15].  One study did not describe short-term HRV 
analysis – therefore, only 24h HRV from this study was included in this review [21].  
Five studies analysed HRV over a 24hr period, four in free living conditions 
[10,16,21,23] and one under more stable conditions in a laboratory [14].  Since short- and 
long-term HRV are not directly comparable, these analyses will be considered separately 
in this review. 
2.3.3 Heart rate variability according to metabolic syndrome status 
Table 2.2 summarizes the eight studies that examined differences in short-term HRV 
between MetS+ and MetS- [10-13,17-21].  Scores ranged from 7-14.   
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Figure 2.1: Study flow diagram 
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Table 2.1: Summary of literature included in the review 
Reference Score N Age 
Range 
(y) 
Country Population MetS 
defini-
tion 
HRV  
analysis 
Assoumou et al, 
2010 [10] 
13 1101 ~65 France Older adults ATPIII 24 h &  
5 min 
Brunner et al, 
2002 [11] 
10 183 45-63 United 
Kingdom 
Working men ATPIII 5 min 
Chang et al, 
2010 [12] 
14 1298 ≥20 Taiwan General 
population 
ATPIII 5 min 
Chang et al, 
2012 [13] 
7 129 19-62 Taiwan Intellectual 
disabilities 
ATPIII 5 min 
Gehi et al, 2009 
[14] 
13 288 45-60 United 
States 
Veteran men AHA 24 h 
Hemmingway et 
al, 2005 [15] 
10 2197 45-68 United 
Kingdom 
Working Men ATPIII 5 min 
Jarczok et al, (in 
press) [16] 
13 2441 17-65 Germany Industrial 
workers 
Harm-
onized 
24 h 
Koskinen et al, 
2009 [17] 
11 2283 24-39 Finland Young adults ATPIII, 
IDF 
3 min 
Lee et al, 2011 
[18] 
7 1027 NR South 
Korea 
Adults with 
Schizophrenia 
ATPIII 5 min 
Min et al, 2009 
[19] 
12 986 20-87 South 
Korea 
General 
population 
ATPIII 5 min 
Min et al, 2008 
[20] 
12 1041 20-87 South 
Korea 
General 
population 
ATPIII, 
IDF 
5 min 
Rasic-
Milutinovic et 
al, 2010 [21] 
10 47 NR Serbia Aged <65y ATPIII 24 h & 
5 min 
Soares-Miranda 
et al, 2012 [22] 
11 163 18-21 Portugal Young adults ATPIII, 
IDF 
5 min 
Stein et al, 2007 
[23] 
12 1267 >65 United 
States 
Older adults ATPIII 24 h 
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Table 2.2: Summary of investigations examining heart rate variability alteration in 
metabolic syndrome. 
 
Reference 
                   MetS+ compared to MetS- 
Total Population Men Women 
Short-term HRV 
Assoumou et al, 
2010 [10] 
 
↓TP, VLF, LF, 
LF/HF, LFnu, HFnu 
NS ↓LFnu, LF/HF 
Brunner et al, 2002 
[11] 
 
NR ↓SDNN, TP, LF, 
HF 
NR 
Chang et al, 2010 
[12] 
 
↓SDNN, HF, LF NR NR 
Chang et al, 2012 
[13] 
 
NS NS ↓TP, VLF, LF 
Koskinen et al, 2009 
[17] 
 
NR ↓HF 
↑LF/HF 
↓HF, HFnu 
↑LFnu, LF/HF 
Lee et al, 2011 [18] Schizophrenia – NS 
Healthy - ↓SDNN, 
RMSSD, LF, HF 
 
NR NR 
Min et al, 2009 [19] ↓SDNN, HF, LF 
 
NR NR 
Min et al, 2008 [20]  ↓SDNN, HF, LF 
 
NR NR 
24h HRV 
Assoumou et al, 
2010 [10] 
 
↓TP, ULF, VLF, LF NS ↓TP, VLF 
Gehi et al, 2009 [14] 
 
NR ↓TP, VLF, LF NR 
Rasic-Multinovic et 
al, 2010 [21] 
↓HF, ↑LF/HF NR NR 
HF – high frequency; HFnu – high frequency, normalized units; HRV – heart rate 
variability; LF – low frequency; LFnu – low frequency, normalized units; MetS+ - with 
metabolic syndrome; MetS- - without metabolic syndrome; NR – not reported; NS – not 
significant; RMSSD – root mean square of successive differences; SDNN – standard 
deviation of normal-to-normal intervals; TP – total power; ULF – ultra low frequency; 
VLF – very low frequency. 
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The six studies that scored highest (10-14) showed HRV differences in MetS+ and MetS- 
women.  Three studies showed that in a general population, SDNN, HF and LF were 
reduced in MetS+ compared to MetS- [12,19,20].  Two large studies, one of older adults 
(aged 65.6y) [10] and one of young adults (aged 29-34) [17] showed that some HRV 
parameters were altered in MetS+ compared to MetS- women, but both showed no 
differences in men.  Young MetS+ women had reduced HFnu and increased LFnu and 
LF/HF [17], while older MetS+ women had reduced LFnu and LF/HF [10].  Contrary to 
these results, in a smaller cohort of middle-aged men (aged 45-63y) SDNN, TP, LF and 
HF were reduced and HR increased in MetS+ compared to MetS-, with no differences in 
LF/HF [11]. 
Two lower scoring studies (7) examining more specific populations showed similar 
results.  There were no differences in HRV in MetS+ compared to MetS- in male adults 
with intellectual disabilities, although MetS+ women with intellectual disabilities had 
reduced TP, VLF and LF [13].  There were no differences in MetS+ versus MetS- in 
schizophrenics, but in healthy adults, MetS+ showed reduced SDNN, RMSSD, LF and 
HF [18].   
Three studies examined 24h HRV differences between MetS+ and MetS- [10,14,21] 
(Table 2.2), all of which received moderate-to-high scores (10-13).  Two studies 
examined middle-aged (aged 46-60y) [14] or older adults (aged 65.6y) [10] and showed 
reduced TP, VLF and LF in MetS+ with no differences between HF or LF/HF.  ULF was 
reduced in older adults with MetS [10], but not in the population of all males [14].  In a 
small sample of the general population aged less than 65y, lnHF was reduced and 
lnLF/HF was increased in MetS+ compared to MetS- [21].  Night-time HRV was 
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reported in one study, which showed that TP, VLF, LF, LF/HF and LFnu were reduced 
and HFnu increased in MetS+ compared to MetS- [10].   
2.3.4 Heart rate variability and the number of metabolic syndrome components present 
Four studies described changes in short-term HRV parameters with increasing number of 
MetS components [10,12,17,20].  All scored moderate-to-high on the modified Downs 
and Black scale (11-14).  Chang et al. [12] showed that SDNN was reduced when one or 
more risk factors were present compared to zero risk factors.  Two studies showed that 
there were no differences in frequency domain measures of HRV until at least three MetS 
risk factors were present [10,12].  Min and researchers [20] reported reductions in HRV 
with increasing number of MetS components, but did not report p-values, so significance 
is unknown.  Koskinen and colleagues [17] showed that the number of MetS components 
present was indirectly related to HF, LF and TP and directly related to LF/HF; however, 
after adjustment for age and resting HR, the inverse relationship to HF and relationship to 
LF/HF persisted in women only. 
The relationship between number of MetS components and HRV was also described by 
three high scoring (12-13) studies that examined 24h HRV [10,14,23].  One study 
examined the association between HRV and the number of MetS risk factors present, in 
which all HRV parameters except for HF were associated with the number of 
components [10].  Another study reported on differences between the presence of 0, 1, or 
≥2 components [23].  SDNN, TP and ULF were lower in individuals with 2 or more 
components compared to those with 0 or one component [23].  α1 was reduced in 
individuals with 1 or ≥2 components compared to those with 0 components, but there 
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were no differences between those with 2 and those with 1 components [23].  In older 
men, it was reported that individuals with all 5 components had an 18-50% reduction in 
HRV values compared to those with zero risk factors and that each one unit increment in 
the number of risk factors present reduced VLF by 8% and LF by 15% [14]. 
 2.3.5 Associations between heart rate variability and individual metabolic syndrome risk 
factors 
Table 2.3 summarizes the six short-term and four 24h HRV studies that used regression 
or correlation to investigates associations between HRV parameters and MetS risk 
factors. 
2.3.5.1 Heart rate variability and waist circumference 
Three moderate-to-high scoring studies (11-13) examining large populations showed 
associations with WC [10,17,20].  WC was negatively associated with SDNN, VLF, LF, 
HF [20], LF/HF and LFnu [10].  Sex differences were present and conflicting.  One study 
of older adults showed that WC was negatively associated with LF/HF and LFnu in 
women, but no associations in men [10], while a study of young adults showed WC to be 
associated with reduced HF, LF and TP in men with no associations in women [17].  
These relationships persisted after adjustment for age and HR.  Three low-to-moderate 
scoring studies (7-11) also showed equivocal results [13,15,22].  There were no 
associations between WC and HRV in young adults aged 18-21 [22], but in women with 
intellectual disabilities, increasing WC was associated with reduced VLF and LF/HF 
[13].  In a large cohort of men aged 45-68y, WC had strong inverse relationships with  
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Table 2.3: Summary of investigations examining associations between HRV and 
individual MetS risk factors. 
Reference ↑ WC ↑ BP ↑ FPG ↑ TG ↓ HDL 
Short-term HRV 
Assoumou et 
al, 2010 [10] 
Men: NS 
Women: 
↓LFnu, LF/HF 
All: ↓LFnu, 
LF/HF 
NS NS NS Men: ↓TP, 
VLF 
Women: 
↓LFnu, 
LF/HF 
All: ↓LFnu, 
LF/HF 
 
Chang et al, 
2012 [13] 
Men: NS 
Women: 
↓VLF, LF/HF 
NS Men: NS 
Women: 
↓TP, HF 
Men: ↓TP, 
VLF, HF 
Women: NS 
Men: 
↓LF/HF 
Women: NS 
 
Hemmingway 
et al, 2005 
[15] 
 
↓SDNN, HF, 
LF, ↑HR 
↓SDNN, 
HF, LF, 
↑HR 
↓SDNN, 
HF, LF, 
↑HR 
↓SDNN, 
HF, LF, 
↑HR 
↓SDNN, 
HF, LF 
Koskinen et al, 
2009 [17]  
 
Men: ↓TP, LF, 
HF 
Women: NS 
Men & 
Women: 
↓TP, LF, 
HF, ↑LF/HF 
 
Men: NS 
Women: 
↓HF 
NS NS 
Min et al, 
2008 [20] 
 
↓SDNN, HF, 
LF 
↓SDNN, 
HF, LF 
↓SDNN, 
HF, LF 
↓SDNN, 
HF, LF 
NS 
Soares-
Miranda et al, 
2012 [22] 
NS SBP: 
↓SDNN, 
RMSSD, 
HF, SD1, 
↑HR 
↓HFnu, 
↑LF/HF 
↓HF, HFnu, 
↑LF/HF, 
HR 
NS 
24h HRV 
Assoumou et 
al, 2010 [10] 
NS Men: ↓TP, 
LF, HF 
Women: NS 
All: ↓TP  
Men: NS 
Women: 
↓HF, 
↑LF/HF 
All: ↓HF 
Men: ↓TP, 
ULF, VLF, 
LF, HF 
Women: NS 
All: NS 
Men: NS 
Women: 
↓TP, ULF, 
VLF, LF 
All: ↓TP, 
ULF, VLF, 
LF 
 
Gehi et al, 
2009 [14] 
↓LF ↓VLF, LF ↓LF ↓ULF, VLF, 
LF, TP 
 
NS 
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Table 2.3 continued     
Jarczok et al 
(in press) [16] 
↓SDNN, 
RMSSD, LF, 
HF 
↓SDNN, 
RMSSD, 
LF, HF 
↓SDNN, 
RMSSD, 
LF, HF 
↓SDNN, 
RMSSD, 
LF, HF 
 
↓RMSSD, 
HF, ↑LF 
Stein et al, 
2007 [23] 
NR NR ↓SDNN, 
VLF, ↑HR 
NR NR 
BP – blood pressure; FPG – fasting plasma glucose; HDL – high density lipoprotein 
cholesterol; HF – high frequency; HFnu – high frequency, normalized units; HR – heart 
rate; HRV – heart rate variability; LF – low frequency; LFnu – low frequency, 
normalized units; MetS+ - with metabolic syndrome; MetS- - without metabolic 
syndrome; NR – not reported; NS – not significant; RMSSD – root mean square of 
successive differences; SDNN – standard deviation of normal-to-normal intervals; TG – 
triglycerides; TP – total power; ULF – ultra low frequency; VLF – very low frequency; 
WC – waist circumference. 
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SDNN, LF and HF [15].  In this study, the relationships between HRV and WC were 
stronger than relationship between HRV and all other MetS risk factors [15].   
Four studies examining 24h HRV scored 13 (high scores).  One study showed that WC 
was associated with all HRV parameters and that WC was the risk factor with strongest 
associations [16], while another study showed no associations [10].  A study of males 
showed that LF was reduced with increased WC [14].  When night-time HRV was 
examined, WC showed no association with HRV [10].   
2.3.5.2 Heart rate variability and blood pressure 
Relationships between BP and short-term HRV are inconsistent in the literature.  One 
moderate-scoring study showed that HF, LF and TP were indirectly, and LF/HF directly 
associated with SBP in men and women when adjustments were made for age, but when 
HR was also adjusted for, only increased LF/HF was associated with increased SBP in 
women [17].  A high-scoring study found that SDNN, VLF, LF and HF were negatively 
related to both SBP and DBP [20], but a study of older adults showed no associations 
between HRV and BP [10].  A moderate-scoring study of young adults showed SBP to be 
associated with reduced SDNN, RMSSD, SD1 and HF and increased HR [22].  All HRV 
parameters had strong linear associations with BP in men [15], but no associations were 
seen in adults with intellectual disabilities [13].   
24h HRV was generally associated with BP.  One study demonstrated that all HRV 
parameters were related with both SBP and DBP, although low HRV was more strongly 
associated with DBP [16].  Another study showed that hypertension was negatively 
associated with TP in older adults, but when sex differences were investigated, 
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hypertension was negatively associated with TP, LF and HF in men, but there were no 
associations in women [10].  One study reported that hypertension was associated with 
VLF and LF in men [14].  Night-time HRV was not associated with BP [10]. 
2.3.5.3 Heart rate variability and fasting plasma glucose 
Associations between FPG and short-term HRV vary.  Three moderate-to-high-scoring 
studies showed differing results.  One showed that all HRV parameters were negatively 
related to FPG [20], while another showed that FPG was associated with reduced HF in 
women, but not in men [17].  However, when HR and age were accounted for, no 
associations persisted [17], nor were there any relationships in older adults [10].  
Moderate-to-low-scoring studies showed that increased FPG was associated with reduced 
HFnu and increased LF/HF in young adults [22] and with reduced HF and TP in women 
with intellectual disabilities [13].  In males, FPG had strong linear associations with all 
HRV parameters [15]. 
In long-term HRV studies, multivariate analysis showed that increased FPG was 
associated with reduced 24h RMSSD, SDNN, HF and LF and increased HR [16].  A 
positive linear relationship was demonstrated between FPG and HR in the range of 4.4-
6.4mmol/L and a negative linear relationship was shown between FPG and both SDNN 
and VLF [23].  A study of older men showed that increased FPG was associated with 
reduced LF [14], while another study showed no associations between FPG and HRV in 
men, but negative and positive associations with HF and LF/HF, respectively, in women 
[10].  One study showed no associations between night-time HRV and FPG [10], while 
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another reported that increased FPG was associated with reduced RMSSD, SDNN, HF 
and LF and increased HR [16].   
2.3.5.4 Heart rate variability and triglycerides 
Differing associations have also been shown between short-term HRV and TG.  Two 
moderate-to-strong studies reported no associations between TG and HRV [10,17], 
though an inverse relationship in women was demonstrated following adjustment for age 
and HR [17].  Another strong study with a broader population showed that all HRV 
parameters studied (SDNN, VLF, LF, HF) were negatively related to TG [20].  
Moderate-to-low scoring studies also showed varying relationships.  In young adults, HF 
and HFnu were indirectly and LF/HF and HR directly associated with TG [22].  Men 
showed strong linear associations between TG and all HRV parameters [15], but men 
with intellectual disabilities showed indirect associations only with HF, VLF and TP [13].   
Long-term HRV studies also have had mixed findings.  One study showed that TG was 
associated with all HRV parameters studied [16], while another showed no associations 
in the whole population or in women [10].  In men, TG was negatively associated with all 
HRV indices except for LF/HF [10], or negatively associated with only ULF, VLF, LF 
and TP [14].  There were no associations between day-time HRV and TG, but TG was 
negatively associated with night-time TP, LF and HF in men [10].  There were no 
relationships between night-time HRV and TG in women [10]. 
2.3.5.5 Heart rate variability and high density lipoprotein cholesterol 
In most studies, HDL was not associated with any short-term HRV parameter 
[15,17,20,22].  However, one strong study showed that LF/HF and LFnu were associated 
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with HDL in the entire population and in older women and TP and VLF were associated 
with HDL in older men [10].  Additionally, LF/HF was associated with HDL in men with 
intellectual disabilities [13]. 
HDL was not associated with 24h HRV in men [10,14], but it was associated with all 
HRV except SDNN in a general population [16], and with 24h TP, ULF, VLF and LF in 
women [10].  HDL was negatively associated with night-time TP and VLF in the whole 
population and with night-time VLF and LF in women, though there were no associations 
in men [10]. 
2.4. Discussion 
The key findings of this systematic review are that: 1) HRV generally is reduced in 
MetS+ compared to MetS- in women, but results in men are inconsistent; 2) SDNN and 
α1 are reduced with increasing number of MetS components present in an individual, 
though differences for other HRV parameters may not be apparent until three MetS risk 
factors are present; and 3) time and frequency domain HRV parameters are associated 
with MetS risk factors and sex differences are apparent.   
Most papers reported on standard frequency domain parameters of HRV.  These findings 
are important because frequency bands are thought to reflect different components of the 
autonomic nervous system.  A number of investigators have shown that the HF band is 
reflective of parasympathetic activity, while the LF band reflects a combination of 
sympathetic and parasympathetic activity and the LF/HF ratio is a measure of 
sympathovagal balance [29].  Papers generally reported that HF and LF were reduced, 
suggesting reduced vagal activity [11,17-20] and that in women, LF/HF was increased 
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[10,17] suggesting altered sympathovagal balance.  Both of these HRV states are 
associated with poor health outcomes, though both lifestyle [30] and pharmacological 
interventions [31] have shown promise in normalizing HRV in MetS patients. 
Non-linear HRV analysis has been used in recent years to describe the qualitative, rather 
than quantitative characteristics of heart rate.  Only one short-term [22] and one long-
term study [23] examined non-linear HRV.   Soares-Miranda and colleagues [22] 
reported that SD1 was reduced in young MetS+ adults compared to MetS-.  SD1 is 
considered to be primarily a measure of parasympathetic activity [32], and supports the 
results from frequency domain HRV analysis.  Stein and researchers [23] examined α1, 
which describes the short-term scaling qualities of the heart rate signal.  α1 was reduced 
when one or more MetS components were present, suggesting that breakdown of fractal-
like R-R interval dynamics may be an early contributor to development of MetS and 
subsequent CVD.  The breakdown of fractal complexity occurs when there is a lack of 
variability and when there is uncorrelated randomness [33].  Fractal breakdown has also 
been associated with co-activation of the sympathetic and parasympathetic nervous 
systems [34,35], which suggests that this pattern of autonomic regulation, which is unlike 
the usual reciprocal interplay between the two autonomic nervous system branches, may 
be an important mechanism in the progression to CVD.  Reduced α1 has been shown to 
predict arrhythmic and non-arrhythmic cardiac mortality in patients with depressed left 
ventricular function following a myocardial infarction [36]. 
Despite these general conclusions, there were inconsistencies between studies.  There are 
a number of potential explanations for these mixed findings.  Data collection methods 
were not consistent between studies.  Specifically, for the short-term data, some ECGs 
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were collected while participants were seated and some were supine.  Posture affects 
HRV and results from the seated position are more reproducible [37].  Data were 
generally collected for 5 min, though one study collected data for only 3 min. Perhaps the 
most important contributor to differences in results was breathing rate during the data 
collection period.  Some studies required their participants to breathe at a constant rate in 
time with a metronome, while others allowed free breathing.  Respiratory sinus 
arrhythmia is the primary contributor to the HF band of frequency domain HRV.  In 
persons with low breathing rates (less than 0.15Hz), this increase of power will show in 
the LF band instead.  Despite these methodological variances, differences in HRV 
according to MetS status in women were consistently shown, while differences in men 
were generally lacking. 
The findings of this systematic review are important as they give insight into mechanisms 
underlying the development of MetS and subsequently CVD and T2D.  A review of 
autonomic nervous system function in MetS showed that the individual risk factors – 
obesity, hypertension, hyperglycemia and dyslipidemia – all were associated with 
increased sympathetic and reduced parasympathetic activity [38].  It has been suggested 
that autonomic alterations may precede risk factor development [4], and this is supported 
by longitudinal studies which have found that individuals who developed CVD or T2D 
over an observational study period generally had lower baseline HRV than those who did 
not develop disease [5-7,39].  While this systematic review supports the hypothesis that 
autonomic dysfunction is associated with MetS in women, the cross-sectional design of 
the studies included does not allow causality to be inferred.  Studies examining 
differences in HRV according to presence of MetS risk factors could offer some insight 
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into causality on the premise that, if autonomic dysfunction precedes development of 
MetS, it would be expected that HRV would already be reduced when only one or two 
components were present compared to those with no risk factors.  With the exception of 
SDNN and α1, altered HRV was not apparent until three or more risk factors were 
present.  However, while this may suggest that HRV is not reduced until MetS is present, 
it may be that those with lower HRV are more likely to accumulate three or more risk 
factors, and therefore develop MetS compared to those with higher HRV, who may only 
develop one or two risk factors.  Robust longitudinal studies are needed for clarification. 
Insulin resistance has been hypothesized as an underlying mechanism responsible for the 
clustering of MetS risk factors in individuals [40].  Chang and colleagues [12] examined 
the association of HRV and insulin resistance with the number of MetS components 
present in an individual.  They showed that HRV was already altered in persons with one 
MetS risk factor, but insulin resistance was not apparent until two MetS factors were 
present.  Thus, it was suggested that autonomic modifications may precede changes in 
insulin resistance.  Interestingly, sympathetic hyperactivity is associated with insulin 
resistance [41-43].  This suggests that one of the reasons for discrepancies in the 
literature regarding associations between MetS risk factors and HRV may be the presence 
of insulin resistance.  Since all five components are associated with insulin resistance, it 
may actually be insulin resistance and not the MetS risk factors per se that is responsible 
for reductions in HRV.  This may also explain the underlying mechanism for reduced 
HRV in those with three or more compared to those with two or fewer components.   
There is no previously published systematic review of the associations between HRV and 
MetS.  Robust methods were used for this review, which included strategies to further 
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seek out articles beyond simple database searches.  However, articles were limited to 
those published in English.  Additionally, there is potential for publication bias.  Studies 
reporting non-significant differences between MetS+ and MetS- may not have been 
accepted for publication, and therefore, lack of difference between MetS+ and MetS- may 
be under-reported in the literature.   
There were considerable differences between the studies included in this review, which 
prevented meta-analysis.  Differences in data collection, including patient position (i.e. 
supine versus seated), breathing protocol (spontaneous versus paced), length of ECG 
recording and type of HRV analysis all affect HRV, and therefore prevent data synthesis.   
Since studies included in this review were cross-sectional in design, causality cannot be 
inferred.  Well designed longitudinal studies with robust measures and appropriate 
control or adjustments for confounding variables are needed to examine associations 
between HRV and the progression of cardiometabolic risk factors to CVD. 
Few studies reported associations between MetS risk factors and non-linear HRV 
parameters.  Examination of these relationships could offer unique insight into 
mechanisms underlying the development of risk factors and disease. 
In conclusion, this systematic review of the literature showed that HRV is reduced in 
women with MetS, though findings in men are inconclusive.  Although HRV has been 
shown to be reduced with increasing presence of MetS components, SDNN and α1 are the 
only parameters that were reduced with fewer than three risk factors in combination.  
Additionally, HRV is associated with all individual MetS risk factors, though 
associations vary by population.  Future studies should use consistent methods to allow 
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for better comparability between studies.  Additionally, more comprehensive analyses 
should be performed to ensure that confounders are appropriately accounted for and to 
investigate potential mechanisms. 
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CHAPTER 3 
Associations between heart rate variability, insulin resistance and metabolic 
syndrome risk factors – a cross-sectional study 
3.1 Introduction 
Heart rate variability (HRV) has been utilized in the non-invasive assessment of cardiac 
autonomic regulation.   Alterations in HRV parameters including reduced standard 
deviation of normal-to-normal RR intervals (SDNN) and reductions in the HRV spectral 
frequency bands have been shown to predict cardiac and all-cause mortality in patients 
with cardiovascular disease (CVD) [1,2] and in the general population [3,4].  
Additionally, low HRV may predict the onset of coronary heart disease in individuals 
with type 2 diabetes mellitus (T2D) [5].  The metabolic syndrome (MetS) is an important 
clinical  clustering of cardiovascular risk factors, which increases the risk of developing 
CVD and T2D [6].  It is unclear whether a relationship between HRV and MetS could 
provide an early marker of CVD and T2D risk.    
The Cardiovascular Risk in Young Finns Study investigated the association between 
three-minute supine HRV and MetS components (n=2283) [7].  This study showed that in 
frequency domain analysis, the number of MetS components present was inversely 
related to high- and low-frequency (HF, LF) and total power (TP) and directly related to 
the LF/HF ratio in women [7].  This study was, however, limited to persons between the 
ages of 24 and 39 years of age, so findings cannot be generalized to a broad population.  
Min and colleagues [8] examined the relationship between five-minute seated HRV and 
MetS in a sample of Korean men and women aged 20-87 years (n=1041).  They found 
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that the logarithmically transformed values of the SDNN, LF, HF and very low frequency 
(VLF) were lower in those with MetS compared to those without MetS [8].   
Each MetS component exhibits different associations with HRV parameters, though there 
are many discrepancies between studies.  Although there is no single risk factor that 
appears to be consistently related to HRV, generally, waist circumference (WC), systolic 
(SBP) and diastolic blood pressure (DBP), fasting plasma glucose (FPG) and 
triglycerides (TG) have strong support from the majority of studies examining short-term 
HRV [7-12], while high density lipoprotein cholesterol (HDL) has only shown 
association with HRV in two studies [9,11].  Relationships between MetS, the individual 
components of MetS and non-linear short-term HRV have only been examined in one 
published study to date and this study only examined Poincaré plot parameters in a young 
population aged 18-21 years [12].  To date, the relationship between other non-linear 
parameters, including detrended fluctuation analysis short term scaling exponent (α1) and 
approximate entropy (ApEnt), have not been examined in MetS, nor have Poincaré plot 
parameters been examined in a more representative population of adults. 
Insulin resistance has been implicated as an important mechanism linking the clustering 
of MetS risk factors and autonomic dysfunction, ultimately leading to CVD and T2D 
[13,14].  Chang and colleagues [15] noted that HRV was reduced in individuals with one 
risk factor, but insulin resistance was not apparent until two risk factors were present.  
However, the relationships between HRV, insulin resistance and MetS have not been 
studied. 
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Therefore, the purpose of this study was three-fold: first, to determine whether 
individuals with MetS would have abnormal linear and non-linear HRV compared to 
those without MetS; second, to determine which MetS risk factors were most strongly 
associated with HRV parameters (both linear and non-linear); and third, to examine 
whether insulin resistance was associated with HRV.  It was hypothesized that all HRV 
parameters would be reduced in MetS; that MetS risk factors except for HDL would be 
associated with HRV parameters; and that insulin resistance would be associated with 
HRV parameters. 
3.2 Methods 
This study was part of a multicentre trial conducted between August 2009 and December 
2011 at the Gateway Rural Health Research Institute (Seaforth, Ontario) and the 
Laboratory for Brain and Heart Health at Western University (London, Ontario).   
Participants were eligible if they were aged 18-70 years and presented with at least one 
MetS risk factor according to published guidelines [16].  Exclusion criteria were SBP > 
180 mmHg and/or DBP > 110mmHg; type 1 diabetes; history of myocardial infarction, 
angioplasty, coronary artery bypass or cerebrovascular ischemia/stroke; symptomatic 
congestive heart failure; atrial flutter; unstable angina; unstable pulmonary disease; use of 
medications known to affect heart rate (HR); second or third degree heart block; history 
of alcoholism, drug abuse or other emotional cognitive or psychiatric problems; 
pacemaker; unstable metabolic disease; and orthopedic or rheumatologic problems that 
could impair the ability to exercise.  In total, 224 participants (aged (mean±SD) 57.2±9.0 
y, range 23-70y; 72% female) provided informed consent and volunteered for this study, 
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which was approved by the University of Western Ontario Research Ethics Board 
(#15828).  
Participants reported to the laboratory following an overnight fast, where they were 
assessed for MetS risk factors.  WC was measured at the midpoint between the iliac crest 
and last rib [17], and participants were considered at risk if WC was greater than 88cm 
(women) or 102cm (men) [16].  Supine BP was calculated as the average of the last two 
of three measurements taken at one minute intervals (BpTRU™, VSM MedTech Ltd., 
Coquitlam, BC or manual).  A resting SBP ≥ 135 mmHg and/or DBP ≥ 85 mmHg 
qualified as a MetS risk factor [16].  Blood was drawn and sent to a central laboratory for 
FPG, TG, HDL and insulin analysis.  MetS risk factors were FPG ≥ 6.1 mmol/L, TG ≥ 
1.7 mmol/L and HDL ≤ 1.03 mmol/L (men) or 1.29 mmol/L (women) [16].  Those 
presenting with three or more risk factors were categorized as with MetS (MetS+), and 
those with two or fewer risk factors were considered without MetS (MetS-) [16].  
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated with 
standard methods [18].   
Following a light, standardized snack, participants were instrumented for collection of a 
lead II ECG recording.  A respiratory belt (Pneumotrace II, ADInstruments, Colorado 
Springs, Colorado) was secured around the thorax for collection of respiratory rate.  RR 
intervals (RRI) were collected during ten minutes of supine rest.  External stimuli, such 
as light and noise were controlled to ensure signal stability.  Participants were instructed 
to remain still and awake.  All measures were sampled at 1000Hz, input into a data 
acquisition board (PowerLab ML795, ADInstruments) for analog-to-digital signal 
conversion with LabChart7Pro software (ADInstruments) and stored for offline analysis.  
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Lab Chart files were converted to text files for analysis with HRV software (Hearts v7, 
Heart Signal Co., Oulu, Finland).   
A predictive stepping test was used to estimate maximal oxygen uptake (VO2max).  The 
protocol has been published elsewhere [19].  Briefly, participants stepped up and down a 
set of two 20cm stairs, 20 times, at a pace considered normal. Age, sex, body weight, 
radial pulse measured immediately upon completing the step test and time to complete 
test were entered into the predictive equation. 
HRV Analysis 
Editing of the HR time series was performed by a single investigator.  All ECG signals 
were manually scanned for ectopic or non-sinus beats, which were deleted from the time 
series.  90% of data were needed for inclusion.  Time domain HRV analyses included 
HR, SDNN and the root square mean of successive differences (RMSSD).  The HRV 
spectrum was computed with the non-parametric fast Fourier transform method.  LF 
(0.04-0.15Hz), HF (0.15-0.4Hz), LF/HF and TP were examined.  A Poincaré plot was 
formed by plotting each RRI against the following one to create a scatter plot.  The 
standard deviation of the width (SD1) and length (SD2) were calculated.  The detrended 
fluctuation analysis method was used to examine fractal characteristics of heart rate 
fluctuations.  The root-mean square fluctuations of integrated and detrended data were 
measured in observation windows and then plotted against the size of the window on a 
log-log scale.  α1 was calculated from the slope of the line (from 4-11 beats).  ApEnt 
quantifies the regularity of time series data by calculating the likelihood that runs of 
patterns that are close will remain close on the next incremental comparison.  A greater 
68 
 
ApEnt value represents greater unpredictability in a system.  ApEnt was calculated from 
500 beats and was computed with length, m=2 and tolerance, r=20% 
Statistical Analysis 
In total, 23 participants were removed from analysis due to poor data quality, excessive 
non-sinus rhythm beats or missing data.  An additional four were removed from ApEnt 
analysis as 500 heart beats were not available for analysis.  Insulin was not analyzed in 
28 participants, who were then excluded from analysis including HOMA-IR.  Unpaired t-
tests were used to examine differences between normally distributed HRV parameters in 
MetS+ versus MetS-.  Welch’s correction was used for variables with unequal variance.  
A two-sample Wilcoxon test was used when variables were not normally distributed.  
Since sex differences have been demonstrated [7,9] analyses were run on the entire group 
and separately for men and women.  Multiple linear regression was used to determine 
which components of MetS were associated with HRV parameters, while adjusting for 
other variables.  An a priori decision was made to force age, sex, study site and VO2max 
into the model to account for potential confounding variables.  All MetS components 
were initially included in the model and the model was run using a backward elimination 
model-building algorithm, with alpha set at 0.1, serially removing the least important 
variable.  Regression diagnostics were run to test for influential observations and outliers, 
which were removed when necessary.  To test associations with insulin resistance, 
multiple linear regression models including HOMA-IR were completed as above.  Data 
are presented as mean ± standard deviation (SD) for normally distributed variables, as 
median and interquartile range (IQR) for non-normally distributed variables, and as 
regression coefficients (beta estimates) and 95% confidence interval (CI) for multiple 
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linear regression results, unless otherwise stated.  Statistical analysis was performed with 
R Statistical Software (version 2.15.1) [20].   
3.3 Results 
Participant Characteristics  
Participant characteristics are shown in Table 3.1.  Age was similar in MetS+ and MetS-.  
As expected, MetS+ had greater HOMA-IR, WC, SBP, DBP, FPG and TG, and lower 
HDL compared to MetS-.  Additionally, there were no differences in fitness.  In women, 
MetS+ had greater HOMA-IR, SBP, DBP, FPG and TG, and lower HDL compared to 
MetS-, but there were no differences in WC.  In men, TG was greater and HDL less in 
MetS+ compared to MetS-, but there were no differences in HOMA-IR, WC, SBP, DBP 
or FPG.  VO2max was higher and HDL lower in men compared to women. 
Heart rate variability in participants with or without metabolic syndrome 
Overall, there were no differences in time domain HRV parameters between groups in the 
whole population or in men.  Time domain HRV analysis in women revealed that SDNN 
was lower (38.0(27.0) ms, 44.5(29.3) ms; p=0.020) and HR higher (68(13) bpm, 64(12) 
bpm; p=0. 018) in MetS+ compared to MetS-, but there were no differences in RMSSD. 
After logarithmic transformation for normality, lnLF (5.81±1.09 ln ms2, 6.11±1.00 ln 
ms2; p=0.044) was lower in MetS+ than MetS-, with no differences in lnHF, lnTP or 
LF/HF.  In men, there were no differences in frequency domain measures of HRV 
between MetS- and MetS+.  In women, lnLF (5.73±1.06 ln ms2, 6.13±1.05 ln ms2; 
p=0.022) and lnTP (6.48±1.07 ln ms2, 6.87±1.04 ln ms2; p=0.030) were lower in  
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Table 3.1: Participant Characteristics 
 MetS- MetS+ p  
(MetS- 
vs 
MetS+) 
p  
(Men vs 
Women) 
n  
     Men 
     Women 
95 
21 
74 
129 
41 
88 
  
Age (y)  
     Men 
     Women 
58(12) 
57(12) 
58(11) 
59(10) 
59(9) 
59(11) 
0.778 
0.451 
0.887 
0.75 
WC (cm)  
     Men 
     Women 
103.3±14.6 
105.6±13.0 
102.6±15.0 
107.3±11.1 
109.0±10.6 
106.5±11.3 
0.036* 
0.307 
0.089 
0.09 
SBP (mmHg)  
     Men 
     Women 
131(25) 
135(22) 
130(23) 
135(17) 
134(15) 
138(20) 
0.020* 
0.914 
0.014* 
0.84 
DBP (mmHg)  
     Men 
     Women 
80±11 
84±11 
79(11) 
85±11 
86±10 
84(13) 
0.008* 
0.596 
0.009* 
0.06 
FPG (mmol/L)  
     Men 
     Women 
5.1(0.8) 
5.4(0.5) 
5.0(0.6) 
5.3(1.2) 
5.4(1.2) 
5.3(1.2) 
0.018* 
0.726 
0.019* 
0.15 
TG (mmol/L)  
     Men 
     Women 
1.01(0.56) 
1.13(0.63) 
1.00(0.31) 
1.75(0.98) 
1.77(1.08) 
1.75(0.93) 
<0.001* 
0.002* 
<0.001* 
0.16 
HDL (mmol/L) 
     Men 
     Women 
1.57(0.50) 
1.21(0.30) 
1.65(0.42) 
1.12(0.36) 
0.96(0.21) 
1.19(0.31) 
<0.001* 
0.002* 
<0.001* 
<0.001 
VO2max (ml/kg/min) 
     Men 
     Women 
30.9±6.3 
35.8±4.2 
29.6±6.2 
30.4±5.9 
34.9±5.2 
28.3±4.9 
0.510 
0.527 
0.146 
<0.001 
HOMA-IR  
     Men 
     Women 
1.56(1.19) 
1.77(0.58) 
1.33(1.23) 
2.80(2.47) 
2.95(2.59) 
2.62(2.41) 
<0.001* 
0.051 
<0.001* 
 
DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density 
lipoprotein cholesterol; HOMA-IR, insulin resistance; MetS-, without metabolic 
syndrome; MetS+, with metabolic syndrome; SBP, systolic blood pressure; TG, 
triglycerides;VO2max, maximum oxygen uptake; WC, waist circumference. 
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MetS+ compared to MetS-, but there were no differences in lnHF, LF/HF (Figure 3.1). 
Overall and in men, there were no differences in non-linear HRV parameters between 
MetS+ and MetS-.  In women, SD2 (46.8(31.6) ms, 58.4(29.9) ms; p=0.014) was reduced 
in MetS+ compared to MetS-, but there were no differences in other non-linear HRV 
measures (Figure 3.2). 
Heart rate variability and metabolic syndrome components 
Table 3.2 presents the results for each best-fit multiple linear regression model, including 
predictors with alpha <0.1.  All models were adjusted for age, sex, study site and fitness 
and MetS components were tested for inclusion in the final models.  For time domain 
parameters, testing at a conventional alpha level of 0.05, only DBP was associated with 
HR (p=0.010), although SBP remained in the model to improve the fit.  TG was 
associated lnSDNN (p=0.029), and both WC (p=0.037) and FPG (p=0.012) were 
associated with lnRMSSD. 
In the frequency domain, TG (p=0.047) and HDL (p=0.039) were associated with lnLF 
and WC was associated with lnHF (p=0.024) and lnLF/HF (p<0.001).  No MetS 
components were associated with lnTP (p>0.05).   
For non-linear HRV parameters, WC (p=0.030) and FPG (p=0.018) were associated with 
SD1, and FPG (p=0.009), TG (=0.048) and HDL (p=0.002) were associated with SD2.  
WC was associated with α1 (p=0.023) and FPG was associated with ApEnt (p=0.033).  
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Figure 3.1: Differences in frequency domain heart rate variability.  Black bars, 
women without metabolic syndrome; white bars, women with metabolic syndrome; 
striped bars, men with metabolic syndrome; dotted bars, men with metabolic 
syndrome.  * p<0.05 compared to women without metabolic syndrome. 
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Figure 3.2: Differences in Poincaré plot variables.  Black bars, women without 
metabolic syndrome; white bars, women with metabolic syndrome; striped bars, 
men without metabolic syndrome; dotted bars, men with metabolic syndrome.   
* p<0.05 compared to women without metabolic syndrome. 
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Table 3.2: Multiple linear regression results with metabolic syndrome risk factors 
 β 95% Confidence 
Interval 
p-value F-statistic Adjusted R2 
HR 
     SBP 
     DBP 
 
-0.053 
0.009 
 
(-0.006, 0.000) 
(0.002, 0.016) 
 
0.062 
0.012* 
6.289 0.209 
lnSDNN 
     TG 
     HDL 
 
-0.074 
0.358 
 
(-0.141, -0.008) 
(-0.011, 0.727) 
 
0.029* 
0.057 
3.380 0.097 
lnRMSSD  
     WC 
     FPG 
 
-4.38x10-5 
-0.260 
 
(-8.51x10-5, -2.52x10-6) 
(-0.462, -0.585) 
 
0.037* 
0.012* 
3.556 0.125 
lnLF 
     TG 
     HDL 
 
-0.152 
0.880 
 
(-0.303, -0.002) 
(0.043, 1.717) 
 
0.047* 
0.039* 
3.106 0.087 
lnHF 
     WC 
 
-4.55x10-5 
 
(-8.50x10-5, -5.97x10-6) 
 
0.024* 
3.404 0.078 
lnTP 
     TG 
 
-0.125 
 
(-0.271, 0.020) 
 
0.091 
4.553 0.082 
LF/HF 
     WC 
     SBP 
 
4.64x10-5 
-2.34x10-4 
 
(1.95x10-5, 7.32x10-5) 
(-5.08x10-4, 4.11x10-5) 
 
<0.001* 
0.095 
2.877 0.079 
lnSD1 
     WC 
     FPG 
 
-3.41x10-5 
-0.125 
 
(-4.49x10-5, -2.31x10-6) 
(-0.229, -0.213) 
 
0.030* 
0.018* 
3.436 0.110 
SD2 
     FPG 
     TG 
     HDL 
 
-4.798 
-3.457 
30.847 
 
(-8.387, -1.209) 
(-6.878, -0.035) 
(11.540, 50.152) 
 
0.009* 
0.047* 
0.002* 
4.054 0.145 
α1 
     WC 
 
-1.07x10-5 
 
(1.51x10-6, 2.00x10-5) 
 
0.023* 
2.346 0.045 
ApEnt 
     FPG 
 
-6.31x10-3 
 
(-1.21x10-2, -5.07x10-4) 
 
0.033* 
2.351 0.039 
ApEnt, approximate entropy; α1, short-term scaling exponent; DBP, diastolic blood 
pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; HF, 
high frequency power; HR, heart rate; LF, low frequency power; RMSSD, root mean 
square of successive differences; SBP, systolic blood pressure; SD1, Poincaré plot width; 
SD2, Poincaré plot length; SDNN, standard deviation of normal to normal intervals; TG, 
triglycerides; TP, total power; WC, waist circumference. 
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Heart rate variability and insulin resistance 
Table 3.3 shows multiple linear regression results with HOMA-IR included as a variable.  
HOMA-IR was associated with HR (p=0.003) and improved the fit of the model 
(Adjusted R2 0.220).  The models for lnSDNN, lnLF and ApEnt were essentially 
unchanged with the addition of HOMA-IR, while the inclusion of HOMA-IR in the 
models for lnRMSSD, lnHF, lnTP, LF/HF, lnSD1, SD2 and α1 reduced the adjusted R2 
value.   
3.4 Discussion 
The main finding of this study was that HRV profiles were less favourable in MetS+ 
compared to MetS-, and that differences existed in both linear and non-linear HRV 
parameters in women, but not in men.  Additionally, this study showed that HDL and TG 
were associated with overall variability, but abdominal obesity and FPG were associated 
with beat-to-beat HRV controlled primarily by the parasympathetic nervous system.  This 
study was the first to report that Poincaré plot analysis showed reduced parameters in 
MetS+ compared to MetS- in women, but not men.  SD2, which was reduced in women, 
is considered a marker of long-term variation [21,22].  Physiological modelling showed 
that the length of the Poincaré plot was correlated equally to both LF and HF spectral 
powers, which suggests that it is affected by both sympathetic and parasympathetic input 
[22,23].  Multiple linear regression showed that 14.5% of the variance of SD2 was 
explained by FPG, TG and HDL in this population.  There were no differences in SD1, α1 
or ApEnt in MetS+ compared to MetS-.  Interestingly, all of the non-linear parameters 
that were not significantly different between MetS+ and MetS- were shown by multiple  
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Table 3.3: Multiple linear regression results with metabolic syndrome risk factors 
and HOMA-IR 
 β 95% Confidence 
Interval 
p-value F-statistic Adjusted R2 
HR 
     IR 
     SBP 
     DBP 
 
1.298 
-0.144 
0.039 
 
(0.460, 2.135) 
(-0.247, -0.040) 
(0.039, 0.409) 
 
0.003* 
0.007* 
0.017* 
6.550 0.220 
lnSDNN 
     TG 
     HDL 
 
-0.090 
0.500 
 
(-0.160, -0.022) 
(0.057, 0.870) 
 
0.011* 
0.017* 
2.822 0.092 
lnRMSSD  
     TG 
     HDL 
 
-0.208 
1.086 
 
(-0.421, 0.005) 
(-0.172, 2.344) 
 
0.055 
0.090 
2.260 0.053 
lnLF 
     SBP 
     DBP 
     TG 
     HDL 
 
0.011 
-0.021 
-0.173 
1.152 
 
(-0.001, 0.022) 
(-0.041, -0.001) 
(-0.331, -0.016) 
(0.233, 2.071) 
 
0.069 
0.039* 
0.031* 
0.014* 
3.138 0.097 
lnHF 
 
   3.200 0.047 
lnTP 
     TG 
 
-0.143 
 
(-0.293, 0.006) 
 
0.060 
3.262 0.064 
LF/HF 
     WC 
     TG 
 
3.27x10-5 
-1.57x10-2 
 
(5.13x10-8, 6.53x10-5) 
(-3.17x10-2, 4.84x10-4) 
 
0.049 
0.057 
1.876 0.056 
lnSD1 
     TG 
     HDL 
 
-0.104 
0.535 
 
(-0.210, 0.002) 
(-0.095, 1.164) 
 
0.055 
0.096 
2.310 0.055 
SD2 
     TG 
     HDL 
 
-4.607 
36.813 
 
 (-8.336, -0.879) 
(14.917, 58.710) 
 
0.016* 
0.001* 
3.478 0.111 
α1 
 
   1.524 0.012 
ApEnt 
     HDL 
 
-0.111 
 
(-0.221, 0.002) 
 
0.046 
1.873 0.028 
ApEnt, approximate entropy; α1, short-term scaling exponent; DBP, diastolic blood 
pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein cholesterol; HF, 
high frequency power; HR, heart rate; HOMA-IR, insulin resistance; LF, low frequency 
power; RMSSD, root mean square of successive differences; SBP, systolic blood 
pressure; SD1, Poincaré plot width; SD2, Poincaré plot length; SDNN, standard deviation 
of normal to normal intervals; TG, triglycerides; TP, total power; WC, waist 
circumference. 
  
77 
 
linear regression to be associated with WC or FPG.  For both MetS+ and MetS- groups, 
mean WC was greater than sex-specific cut-offs for MetS risk, and mean FPG lower than 
MetS thresholds.  Hence, any alterations in these HRV parameters that would have been 
attributed to increased WC as a MetS risk factor may have been equal in both groups. 
The results of this study agree with most others that HRV is reduced in women with 
MetS, but not in men [7,9].  However, some studies have shown alterations in HRV in 
men with MetS [10].  In the present study, the only MetS risk factors that were different 
between men with and without MetS were TG and HDL, with no differences between 
WC, BP or FPG.  Additionally, fitness (VO2max) was higher in men than women.  
Therefore, the MetS+ men may have been healthier than the MetS+ women, which may 
explain why HRV was not reduced in MetS+ men.   
Generally, studies have shown that HRV analysed in both the time and frequency 
domains are reduced in MetS, but differences exist regarding which parameters are 
affected.  One study showed that all time and frequency domain HRV was reduced in 
MetS+ compared to MetS- with the exception of LF/HF [10], while others showed no 
differences at all [11,24].  Another study showed that participants with MetS had 
reductions in only SDNN, HF, LF and VLF [8].  This is similar to the present study, 
which showed reduced lnSDNN and lnLF in MetS+ compared to MetS-, but there were 
no differences in HF.  These finding are important as two longitudinal studies of initially 
healthy populations showed that reduced SDNN, lnLF and lnHF were associated with an 
increased risk of developing coronary heart disease [25,26].  Frequency domain measures 
and SDNN were primarily predicted by TG and HDL in this study, which suggests that 
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management of dyslipidemia may be an important MetS treatment strategy to normalize 
the HRV parameters that predict mortality. 
In this study, lnHF, RMSSD and SD1 were not different between MetS+ and MetS-.  
These HRV parameters are reduced or abolished with atropine administration, suggesting 
a strong contribution from the parasympathetic nervous system [22,27].  Reduced HF is 
predictive of mortality in healthy populations [25,26] and following myocardial 
infarction [2].  Although there were no differences between groups in this study, both 
groups had lower HRV than a healthy population [28].  Our population did not include 
healthy people with no MetS risk factors.  Therefore, parameters reflective of vagal 
activity might actually be more sensitive to disease and the presence of one risk factor 
may be sufficient to alter cardiac autonomic health.  An alternate explanation may be that 
our population was older (average aged 57.1years).  Reductions in HRV parameters 
reflective of vagal activity may have been due to age or other factors rather than presence 
of MetS risk factors as the model to predict HF only explained 7.8% of the variance. 
It is generally accepted that there is no HRV parameter that is reliably indicative of 
sympathetic activity.  A recent review of autonomic activity in MetS reported a strong 
association between sympathetic activity and HR in a MetS population; hence authors 
suggested that HR may be a valid surrogate measure of sympathetic activity [29].  In the 
current study, MetS+ had a higher HR than MetS- in women.  Though more research is 
needed to confirm validity of the measure, this may suggest that sympathetic activity is 
increased in MetS.  Reviews of the literature have shown that sympathetic activity 
measured by norepinephrine spillover and muscle sympathetic nerve activity is increased 
in MetS [14,29,30].  It has been hypothesized that increased sympathetic activity in MetS 
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may be associated with increased insulin resistance.  In this population, both HR and 
HOMA-IR were increased in MetS+ women but not in men.  Interestingly, despite a 
broad range of HOMA-IR, average HOMA-IR indicated normal insulin resistance in both 
MetS+ and MetS-.  This study does not support previous hypotheses that insulin 
resistance was a mechanism involved in alterations in HRV in MetS [15].  Addition of 
HOMA-IR to the multiple linear regression models generally reduced the adjusted R2 
term, suggesting that it actually worsened the fit of the model.  However, for HR and 
lnLF– HRV parameters that arguably may be associated with sympathetic activity – 
addition of HOMA-IR modestly improved the model.  These findings suggest that 
alterations in insulin resistance may be associated with increased sympathetic activity, 
but findings do not support associations between insulin resistance and other HRV 
parameters in MetS. 
Potentially a significant contribution to the discrepancy in results may be that MetS 
components may affect HRV to a different extent.  Liao and researchers [31] showed that 
in patients with multiple metabolic syndrome (defined as any combination of 
hypertension, diabetes and dyslipidemia), there was a general reduction in HRV 
parameters with an increasing number of metabolic disorders in a single individual (with 
the exception of LF/HF, which showed no difference).  However, there were differences 
based on which metabolic risk factors were present.  A combination of hypertension with 
either dyslipidemia or diabetes had additive effects, while a combination of diabetes and 
dyslipidemia had the lowest HRV, with more than simply additive effects [31].  Thus, 
simply the presence (or not) of MetS may not be sufficient to cause alterations in HRV, 
rather, specific combinations of risk factors may be a more important determinant.   
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Since this was a cross-sectional study causality cannot be inferred.  This study was 
limited to a sample of relatively healthy adults – therefore findings may not be 
generalizable to populations with overt disease.  Participants were not restricted from 
taking medications prior to ECG recording.  Since certain anti-hypertensive medications 
are known to improve HRV, these may have affected our results. 
In conclusion, women with MetS have a less favourable HRV profile than women 
without MetS, but these relationships were not apparent in men.  There is no single MetS 
risk factor that independently predicts all HRV parameters.  Insulin resistance improves 
model fit for HRV parameters that may be associated with sympathetic function, but not 
for HRV parameters classically associated with parasympathetic function. 
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CHAPTER 4 
Diabetes and Technology for Increased Activity (DaTA Study):  The effects of 
exercise and technology on heart rate variability and metabolic syndrome risk 
factors1.   
4.1 Introduction 
An increasingly aging, overweight and sedentary population has a greater risk of 
developing cardiovascular disease (CVD) and type 2 diabetes (T2D).  Metabolic 
syndrome (MetS) is a clustering of risk factors including hypertension, dysglycemia, 
dyslipidemia and abdominal obesity.  Clustering of these factors doubles the five-year 
risk of developing CVD and increases the risk of developing T2D five-fold [1].  Expert 
panels have called attention to the importance of targeting the cardiovascular risk factors 
of MetS in order to prevent CVD and T2D [1,2]. 
Heart rate variability (HRV) is a simple, non-invasive measure that can be used to 
quantify autonomic nervous system function [3].  Diminished HRV predicts all cause and 
cardiovascular mortality [4-7], and is associated with MetS risk factors [8-11].  In 
patients with an increased risk of CVD, impaired autonomic function may be especially 
dangerous.  Patients with T2D with low HRV have double the risk of mortality compared 
                                                 
1
 The results from this paper have been published:  (1) Stuckey M, Fulkerson R, Read E, Russell-Minda E, 
Munoz C, Kleinstiver P, et al. Remote monitoring technologies for the prevention of metabolic syndrome: 
the Diabetes and Technology for Increased Activity (DaTA) study. J Diabetes Sci Technol 2011;5(4):936-
944.  (2) Stuckey M, Russell-Minda E, Read E, Munoz C, Shoemaker K, Kleinstiver P, et al. Diabetes and 
Technology for Increased Activity (DaTA) study: results of a remote monitoring intervention for 
prevention of metabolic syndrome. J Diabetes Sci Technol 2011;5(4):928-935.  They are reprinted here 
with permission from the journal. 
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to those with normal HRV [4]. There is evidence that lifestyle changes may have positive 
autonomic effects [12-14], but these modifications may not be maintained long-term [15]. 
In Southwestern Ontario, cardiovascular risk is greater and access to healthcare is less in 
rural communities compared to urban centres.  The incidence of obesity, diabetes and 
hypertension is higher in rural areas, specifically Huron County, compared to nearby 
urban centres (London, Ontario) [16].  Additionally, Huron County has a 27.5% vacancy 
rate for general and family practitioners compared to 0% in London and 20.2% vacancy 
provincially in Ontario [17]. 
Remote monitoring technology has the potential to bridge the gap between healthcare 
providers and patients in underserviced areas.  Remote monitoring programs using 
mobile telephones have effectively reduced individual risk factors in a number of studies.  
Submitting home blood pressure (BP) measurements via short message service (SMS; 
text messaging) and/or internet effectively reduced BP in uncontrolled hypertensive 
patients [18] and obese hypertensive patients[19].  Patients with uncontrolled 
hypertension who took BP measurements with a Bluetooth enabled BP monitor which 
transmitted readings through a cellular telephone to a secure database monitored by 
research personnel improved BP control in diabetics with uncontrolled hypertension [20].  
Studies examining remote monitoring of blood glucose via cellular telephone to manage 
diabetes have had promising, but mixed results.  Some research found that glycated 
haemoglobin (HbA1C) decreased [21-24], while one study showed no change [25].   
Recent systematic reviews have examined the utility of remote monitoring technologies 
for behaviour change in diabetic populations [26,27].  These papers agreed that one of the 
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major shortcomings in the published literature was that the clinical outcome variable was 
measured, but the intended behaviour change was not.  Remote monitoring of behaviour 
change concurrently with physiological measures would allow immediate data 
assessment by practitioners and the ability to provide more appropriate, targeted feedback 
to patients.   
Therefore, the aims of this study were to investigate the feasibility and utility of using 
remote monitoring technology to monitor home BP, blood glucose, HRV and physical 
activity and to examine changes in home and clinic measures following an eight-week 
lifestyle intervention.  It was hypothesized that an intervention to increase physical 
activity supported by home health monitoring technologies, would result in improvement 
in risk factors for CVD and T2D, including MetS risk factors and HRV. 
4.2 Methods  
Twenty-five participants volunteered to participate in this study and provided informed 
consent.  Participants were included if they had at least two MetS risk factors according 
to ATPIII guidelines: waist circumference (WC) ≥ 88cm (women) or 102cm (men); 
resting systolic BP (SBP) ≥ 135 mmHg and/or diastolic BP (DBP) ≥ 85 mmHg; fasting 
plasma glucose (FPG) ≥ 6.1 mmol/L; triglycerides (TG) ≥ 1.7 mmol/L; and high density 
lipoprotein cholesterol (HDL) ≤ 1.03 mmol/L (men) or 1.29 mmol/L (women) [2].  
Exclusion criteria were SBP > 180 mmHg and/or DBP > 110mmHg; type 1 diabetes; 
history of myocardial infarction, angioplasty, coronary artery bypass or cerebrovascular 
ischemia/stroke; symptomatic congestive heart failure; atrial flutter; unstable angina; 
unstable pulmonary disease; use of medications known to affect heart rate (HR) (such as 
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beta blockers), or use of other medication that may interfere with study objectives; 
second or third degree heart block; history of alcoholism, drug abuse or other emotional 
cognitive or psychiatric problems; pacemaker; unstable metabolic disease; and orthopedic 
or rheumatologic problems that could impair the ability to exercise.  One participant 
withdrew from the study shortly following baseline testing due to hospitalization for a 
respiratory illness unrelated to the study.  Twenty-four participants (aged 56.6 ± 9.0y; 6 
male) reported to Gateway Rural Health Research Centre at baseline (V0) and after four 
(V1) and eight (V2) weeks of intervention.  This study was approved by Institutional 
Review Board Services (Aurora, Ontario, Canada; #RP-2008). 
At each visit, BP was measured in the seated position with an automated BP cuff 
(BPTru™, VSM MedTech Ltd., Coquitlam, BC).  Clinic BP was calculated as the 
average of the last two of three measures.  Anthropometric measures included WC 
measured as the midpoint between the lower rib and iliac crest (cm) [28]; body mass 
index (BMI), calculated as weight in kilograms divided by the square of the height in 
metres (kg/m2); and body weight (kg).  Blood was drawn from the anticubital vein and 
samples were sent to a central processing lab for analysis of FPG, lipid profile and 
HbA1C.     
An exercise specialist administered the Step Test Exercise Prescription (STEP™) to 
estimate fitness (VO2max; ml/kg/min) and counsel participants regarding physical activity 
[29].  Participants were instructed to step up and down a set of two steps twenty times at 
a comfortable pace.  HR was measured immediately following the test by palpation of the 
radial artery and input into the prediction equation for calculation of VO2max (Appendix 
1). 
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 A personalized exercise program was prescribed based on the fitness level determined by 
the stepping test and a certified personal trainer helped participants set SMART (specific, 
measurable, attainable, realistic, timed) goals.  Exercise prescription followed American 
College of Sports Medicine [30] guidelines, with a target exercise HR of 70-85% of age 
predicted maximum HR.  Goals included increasing pedometer-monitored steps per day 
with the overall goal of achieving 10,000 steps per day [31].  The exercise prescription 
and goals were updated at V1.   
Home Monitoring  
Participants received a smartphone (Blackberry® Curve 8300, Research in Motion, 
Waterloo, Ontario) equipped with health monitoring software (Healthanywhere™, 
IgeaCare Inc., Markham, Ontario), a Bluetooth™ enabled BP monitor (A & D Medical, 
UA-767PBT, San Jose, California), a glucometer (Lifescan One Touch Ultra2™, 
Milpitas, California, with wireless Bluetooth™ adapter Polymap, PWR-08-03, Tucson, 
Arizona) and a pedometer (Omron, HJ-150, Koyoto, Japan).  One-on-one technology 
training was included at V0 and lasted approximately 30 minutes.  Participants were 
instructed regarding proper use of devices and techniques to get accurate measurements.  
Blood glucose measures were to be submitted twice daily – fasted upon waking and non-
fasted before bed, BP measures were to be submitted three times per week upon waking, 
pedometer steps were to be input nightly, and body weight input weekly.  Real-time 
measurements were sent to a secure central database that was monitored regularly by 
researchers.  Limits were set for blood glucose at 3mmol/L and 15mmol/L, systolic BP 
(SBP) at 60 mmHg and 210 mmHg and diastolic BP (DBP) at 40 mmHg and 120 mmHg.  
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Readings that were outside of these limits triggered alarms that automatically sent a 
message to the study physician’s smartphone to follow up with the participant.   
During the week following V0 and V2 visits, participants received a HR and activity 
monitor (Suunto Memory Belt, Vantaa, Finland), which was worn twice for five minutes 
of seated rest and once for 24 hours.  Data were downloaded from the monitor to a 
personal computer and converted to text files for analysis (Heart Signal Co, Oulu, 
Finland).  Standard deviation of normal to normal R-R intervals (SDNN) was calculated 
from the entire file for both five-minute and 24-hour recordings.  Frequency domain 
analysis was performed on the entire file for five-minute readings, and 24 hour HRV was 
calculated as the average of one hour epochs.  An autoregressive model (order 20) was 
used to estimate power spectrum density for very low frequency (VLF: 0.003-0.04 Hz), 
low frequency (LF: 0.04-0.15 Hz), high frequency (HF: 0.15-0.4 Hz) and total power 
(TP: 0.003-0.4 Hz) [3].  Values were logarithmically transformed to attain normal 
distribution.  Fractal HR dynamics were calculated from the HR time series.  This value 
represents the qualitative characteristics and correlation features of HR behaviour.  The 
root-mean square fluctuations of integrated and detrended data were measured in 
observation windows then plotted against the size of the window on a log-log scale.  The 
slope of the line was calculated (α1) to reflect short term HR behaviour. Recordings with 
less than 80% qualifying beats were excluded from analysis.   
Database and Data Security 
Real-time data were transmitted from the smartphone to the server and database via 
secure internet protocol. Personal identifiers were not stored in the Smartphone.  All 
communication of data between participant devices and the server were encrypted using 
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secure sockets layer (SSL) certificates before storage.  Data transfers between the 
smartphones and the server were encrypted and only accessible using the Verisign 
certified HTTPS session that employs SSL with a 128-bit encryption across all channels 
for the Smartphone to server (key pair) and server to database. All data were encrypted 
end-to-end according to the latest encryption standards and were authenticated and 
checked for integrity to ensure that data was sent from an authorized source and had not 
been tampered with. All clinical variables were transmitted as numbers only, were not 
accompanied by identifiable information and were linked to participant data once on the 
protected server. 
Access to data was limited to authorized researchers with valid user identification and 
passwords. If a smartphone was lost or needed to be replaced, safeguards (secure link) 
were reprogrammed by changing the participant log in and password to ensure personal 
health information was accessed by authorized personnel only. Healthanywhere accounts 
were also controlled and protected remotely so that if a device was lost accounts were 
deactivated to prevent unauthorized access to participant health information.  
Statistical Analysis 
SPSS software (Version 17) was used for analysis.  Paired t-tests were used to observe 
differences between V0 and V2 measures of BP, FPG, lipid profile, fitness, 
anthropometrics and HRV.  Paired t-tests were also used to examine changes in home 
monitoring data from week 1 to week 8 (average of measures sent in week 1 and week 8, 
respectively).  Mean substitution was used for missing data.  Pearson correlation was 
used to determine whether any relationships existed between MetS risk factors and HRV.  
All results are shown as mean ± standard deviation unless otherwise specified.  
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4.3 Results 
Participant characteristics are shown in table 4.1.  At baseline, participants had 3.46 ± 
1.22 of five metabolic risk factors (range 2 to 5).  Based on ATPIII guidelines for MetS 
[2], 95.8% of participants had abdominal obesity, 91.7% had high BP, 33.3% had 
impaired fasting plasma glucose, 62.5% had high triglycerides and 62.5% had low HDL.  
Six participants had T2D at study enrolment, and one was diagnosed with T2D shortly 
after enrolment by remote monitoring blood glucose measurements and confirmed by 
blood draw results.  
Clinic DBP was reduced from 84±8 mmHg to 80±13mmHg (p=0.046) despite no change 
in clinic SBP (V0: 141±10, V2: 139±19; p>0.05) (Table 4.2).  However, the percentage 
of participants with sufficient BP control, defined according to ATPIII criteria (clinic BP 
less than 130/85 mmHg and not medicated for hypertension) increased from 8.3 to 33.3% 
from V0 to V2.  Similar to clinic BP results, there was no change in remotely monitored 
SBP (Week 1: 136±17 mmHg; Week 8: 132±19 mmHg; p>0.05).  DBP on the other hand 
decreased from 88±12 mmHg in week 1 to 84±10 mmHg in week 8 (p<0.001) (Table 
4.3). 
There was no change in clinic (table 4.2) or home monitored blood glucose (table 4.3).  
Likewise, there were no changes in triglycerides, LDL or HDL (table 4.2).  Total 
cholesterol decreased from 5.48±1.27 mmol/L at V0 to 5.19±1.11 mmol/L at V2  
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Table 4.1:  Participant Characteristics 
Characteristics  
n 24 
Age 56.6±8.9 years 
Number of males 6 (25%) 
Metabolic Syndrome Risk Factors (of 5) 3.46±1.22 
Above Metabolic Syndrome Thresholds:  
Waist Circumference 95.8% 
Blood Pressure 91.7% 
Fasting Plasma Glucose 33.3% 
Triglycerides 62.5% 
High Density Lipoprotein Cholesterol 62.5% 
 
  
93 
 
Table 4.2:  Clinic values before and after the eight-week intervention 
Clinic measure V0 V2 p-value 
Waist Circumference (cm) 111.5 ± 9.0 107.7 ± 11.6 0.002* 
Systolic Blood Pressure (mmHg) 141 ± 10 139 ± 19 0.475 
Diastolic Blood Pressure (mmHg) 84 ± 8 80 ± 13 0.046* 
Fasting Plasma Glucose (mmol/L) 6.0 ± 2.4 5.5 ± 1.1 0.221 
Triglycerides (mmol/L) 1.80 ± 1.32 1.53 ± 0.74 0.153 
High Density Lipoprotein 
Cholesterol (mmol/L) 
1.34 ± 0.33 1.35 ± 0.40 0.655 
Low Density Lipoprotein 
Cholesterol (mmol/L) 
3.14 ± 1.54 3.13 ± 1.07 0.983 
Total Cholesterol (mmol/L) 5.48 ± 1.27 5.19 ± 1.11 0.009* 
HbA1C (%) 6.0 ± 0.8 5.9 ±0.6 0.182 
VO2max (ml/kg/min) 29.3 ± 5.6 34.7 ± 7.0 <0.001* 
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Table 4.3:  Home monitoring values during week 1 and week 8 of the eight-week 
intervention 
Home Monitoring Measurement WEEK 1 WEEK 8 p-value 
Systolic Blood Pressure (mmHg) 136 ± 15 133 ± 18 0.165 
Diastolic Blood Pressure (mmHg) 88 ± 10 84 ± 9 <0.001* 
Fasted Morning Blood Glucose 
(mmol/L) 
6.7 ± 2.4 6.3 ± 1.2 0.264 
Non-Fasted Evening Blood Glucose 
(mmol/L) 
7.5 ± 2.8 6.9 ± 1.5 0.213 
Pedometer Steps (steps/day) 5671 ± 1989 6757 ± 2455 0.003* 
Body Weight (Kg) 92.7 ± 14.0 92.1 ± 13.8 0.312 
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(p=0.009).  Waist circumference decreased from 111.5±9.0 cm at V0 to 107.7±11.6 cm at 
V2 (p=0.002), but there was no change in body weight (Table 4.3).   
There was an 18% increase predicted VO2max from 29.34±5.60 ml/kg/min at V0 to 
34.68±7.02 ml/kg/min at V2 (p<0.001).  Pedometer steps increased from 5671±2670 
steps/day in week 1 to 6757±3698 steps per day in week 8 (p=0.003).   
Twelve participants had acceptable 24h HRV recordings both V0 and V2 (table 4.4).  
HFnu increased from 24.5±12.0 at V0 to 28.0±12.1 at V2 (p=0.03) and LFnu decreased 
from 75.5±12.0% at V0 to 72.0±12.1 at V2 (p=0.03) (Figure 4.1).  There were no 
changes in other 24h HRV variables.  Thirteen participants had acceptable 5min HRV 
recordings at both V0 and V2 (Table 4.5).  There were no changes in 5min seated HRV 
over the intervention period.  DBP was correlated with 24h LF:HF (R=0.64).  No other 
relationships were seen between BP and HRV variables.  
Compliance to the self-monitoring protocol was high with overall compliance of 
96.8±4.0%.  Compliance for BP readings was 95.0±14.1%; AM blood glucose 
97.3±4.8%; PM blood glucose 97.8±4.7 %; pedometer steps 96.8±3.7%; and body weight 
91.8±11.4%.  A technology survey was administered at V2 to determine comfort with 
technology and attitudes toward remote monitoring.  Despite the fact that only four 
participants had used smartphones prior to the study, only one participant was not 
comfortable using the smartphone for study purposes.  Using a likert scale from 1-4 
(strongly disagree – strongly agree), it was noted that participants were comfortable with 
the devices and that the remote monitoring protocol resulted in an increased sense of 
security (3.58±0.50), assisted participants in adopting new practices to improve wellbeing  
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Table 4.4: 24h heart rate variability (n=12) 
V0 V2 p-value 
RRI 822 ± 127 849 ± 131 0.288 
HR 75 ± 11 72 ± 11 0.075 
SDNN 150.3 ± 68.9 150.8 ± 57.9 0.962 
lnLF 6.39 ± 0.78 6.41 ± 0.85 0.731 
lnHF 5.18 ± 1.00 5.39 ± 1.09 0.107 
LF/HF 3.9 ± 2.0 3.4 ± 2.6 0.223 
α1 1.367 ± 0.175 1.367 ± 0.171 0.982 
α1, short-term scaling exponent; HF, high frequency; HR, heart rate; LF, low frequency; 
RRI, R-R interval; SDNN, standard deviation of normal to normal intervals; TP, total 
power. 
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Figure 4.1:  Changes in 24 hour LFnu and HFnu heart rate variability from V0 
(black bar) to V2 (white bar). n=12; * p=0.03 
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Table 4.5: 5min seated heart rate variability (n=13) 
V0 V2 p-value 
RRI 796 ± 147 867 ± 172 0.06 
HR 78 ± 13 72 ± 13 0.10 
SDNN 58.6 ± 29.7 62.4 ± 32.6 0.70 
LF 848.2 ± 1048.1 888.0 ± 1254.3 0.91 
HF 307.6 ± 638.7 231.5 ± 359.7 0.67 
LF/HF 5.8 ± 4.3 6.9 ± 7.8 0.60 
α1 1.388 ± 0.182 1.448 ± 0.205 0.10 
α1, short-term scaling exponent; HF, high frequency; HR, heart rate; LF, low frequency; 
RRI, R-R interval; SDNN, standard deviation of normal to normal intervals; TP, total 
power. 
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(3.83±0.38), did not take too much time (1.25±0.44) and did not interfere with activities 
of daily living (1.33±0.48). 
4.4 Discussion 
The main finding of this study was that a technology driven, remote health monitoring 
protocol was feasible in a rural population.  Not only was the technology well accepted 
by the participants, but it also resulted in improved fitness, WC, DBP and total 
cholesterol.  Furthermore, physical activity was increased and HRV was modified despite 
the small sample size.   
Previous studies using remote patient monitoring to control BP have primarily shown 
better results than the current study with BP reductions of 9.1-11.0 mmHg SBP and 7.2-
11.2 mmHg DBP [19,20].  This may be in part due to intervention methodology, as one 
trial included weekly feedback with diet and activity recommendations via text message 
[19].  Our participants received an updated physical activity prescription at V1, but the 
weekly tailoring of lifestyle recommendations likely resulted in greater BP reductions.  
The results of the current study were based on a small sample, in which two participants 
had large increases in BP.  Despite the fact that SBP was unchanged, the percentage of 
participants with adequate BP control (defined by ATPIII MetS criteria < 130/85 mmHg 
and not medicated for BP) increased from 8.3 to 33.3%.  Additionally, it has been 
estimated that even a small reduction in DBP of 2 mmHg would result in a 17% decrease 
in the prevalence of hypertension, a 6% reduction in the risk of coronary heart disease 
and a 15% reduction in the risk of stroke or transient ischemic attack [32].  Therefore, the 
4 mmHg decrease in DBP in the current study may have clinical significance.   
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Studies have reported either decreases [21-24] or no change [25] in HbA1C following 
remote blood glucose monitoring interventions with cellular phones, but changes in 
home-monitored blood glucose were not reported in these studies.  The current study 
showed no change in FPG, but baseline values were lower than in comparable studies and 
the intervention period was shorter than other trials.  Additionally, the American College 
of Sports Medicine and American Diabetes Association joint position statement 
recommends 150 minutes of moderate to vigorous activity per week to reduce blood 
glucose [33].  Considering that the pedometer steps only increased 1086 steps/day, 
participants may not have completed a sufficient amount of moderate to vigorous 
physical activity to affect FPG levels.   
Moderate intensity exercise is recommended as a first-line therapy for MetS [28].  A 
recent study examined the effects of a four-week therapeutic lifestyle modification in 
rural women with MetS and showed that the intervention group had significant reductions 
in body weight, WC, TG, FPG, SBP and LDL and increased HDL [34]. These results 
differ from ours and likely result from differences in intervention delivery.  Oh and 
colleagues [34] provided information booklets to participants at the onset of the trial and 
the intervention group attended education and exercise sessions three times per week for 
two hours each time. Education sessions included both nutrition and exercise advice. In 
the present study tailored exercise prescription was provided, but the exercise was 
unsupervised and dietary advice was not given.  Tjønna and colleagues [35] noted greater 
improvements in MetS in a group of patients completing high intensity interval training 
compared to a continuous moderate exercise group, thus reinforcing that higher 
intensities are better for reducing cardiovascular risk.  Our participants were prescribed 
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moderate intensity activity with a target HR of 70-85% of age-predicted maximum. 
Greater improvements may have been elicited from higher intensity activities, but as our 
participants were in an unsupervised setting, moderate intensity was chosen for safety. 
Although only three participants achieved their step goal and averaged 10,000 steps/day 
by week 8, the increase in PA (mean increase of 1086 steps/day) was sufficient to 
improve markers of MetS. This was despite the fact that the population sample remained 
classified as low active based on daily step count [31]. Individual exercise prescriptions 
were tailored to include other activities as well as walking.  Several participants 
participated in physical activities that are not conducive to pedometer monitoring 
including cycling, swimming, and resistance training.  Therefore, activity may have 
increased more than was measured by the pedometer.  The fact that VO2max increased 
18% (5.34 ml/kg/min) over an 8-week intervention period, suggests that activity levels 
increased during the study.  It is also possible that although the increase in steps per day 
was small, the intensity at which the steps were taken may have been greater.  
Participants were taught how to take their radial pulse and instructed to attain their target 
HR (70-85% of age-predicted maximum) during exercise sessions.  Unfortunately, 
activity intensity was not measured by HR monitor or accelerometry, nor was it recorded 
in an exercise journal. 
HRV is an index of autonomic function that has been shown to be reduced in MetS [8-
11].  Aerobic exercise training in hypertensives has been shown to improve HRV [12-
14], though changes in HRV tend to be more apparent during a stressor that induces 
sympathetic stimulation and parasympathetic withdrawal, than during supine rest.  Since 
HRV in the current study was recorded during seated rest, subtle changes in autonomic 
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function may have occurred that our experimental protocol was not sensitive enough to 
detect.  Since this feasibility study analysed home HRV measurements, the five-minute 
HR recordings for seated HRV analysis were not performed under tightly controlled 
laboratory conditions as recommended [3].  As variations in temperature, light, 
movement and breathing frequency can all affect HRV [3], lack of control of these 
factors may be responsible for the lack of change in short-term HRV.   
Compliance to technology use was higher in this trial (96.79 ± 4.01%) than others 
[21,24].  Compliance to a three-month intervention was only 72% [24], and only two of 
fifteen patients submitted all blood glucose and pedometer readings in a three-month pilot 
study [21].  In the present study, four of 24 participants completed all measures and 12 
others missed less than five of an average 207 total readings.  Discrepancies may be due 
to longer intervention period [21,24] and broader age range [24] compared to the present 
study.  The high compliance in this trial may be explained by the age of our sample, as 
older adults have been shown to have greater compliance than younger adults [24].  This 
may be in part because of fewer commitments to care-giving and employment and greater 
interest in disease prevention.  The high compliance to this study may also be a result of 
the short time period.  A four-month study examining home BP monitoring found that 
weekly compliance was high throughout, but tended to decrease in the last four weeks 
[20].  The participants in the present study with lowest compliance were either shift 
workers (n=2) or had family/care-giver commitments (n=1).   
Other research has shown that one of the greatest barriers to the use of technology is the 
time commitment by physicians to monitor the database [20].  Our study required less 
physician intervention as triage of clinically important measurements was automated thus 
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limiting physician burden. Participants also had access to their personal data throughout 
the study that provided self-reflection, goal setting and self-motivation that served as 
positive and negative support. 
This pilot study was conducted in a sample of highly motivated volunteers and may 
therefore lack external validation.  Since there was no control group, it cannot be 
concluded that improvements in health and activity were a result of self-monitoring 
technologies.  However, the purpose of this pilot study was to test the feasibility and 
utility of a remote monitoring and activity protocol in a rural population.  Future 
randomized trials are needed to compare the impact of an exercise prescription alone with 
that of an exercise prescription combined with self-monitoring.  A baseline pedometer 
measurement was not attained prior to exercise prescription.  Therefore, it is likely that 
habitual activity prior to the onset of pedometer monitoring was in fact lower than the 
week 1 measurements obtained in this study.  Despite the fact that only twelve 
participants had acceptable HR data for 24h HRV analysis and thirteen for 5min HRV, 
modifications were seen in LFnu and HFnu.  However, a greater sample size would have 
been ideal and may have shown greater change.  The technology survey was not a 
validated questionnaire.  However, the responses will still be able to direct protocol 
modifications to improve a larger trail. 
In conclusion, an exercise prescription combined with eight weeks of self-monitoring of 
health and activity measures resulted in increased fitness and activity, which improved 
cardiovascular risk profile as demonstrated by reductions in WC, DBP and total 
cholesterol and improved 24h HRV profile with increased HFnu and reduced LFnu. 
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CHAPTER 5 
Effects of a mHealth exercise intervention on heart rate variability and metabolic 
syndrome risk factors in primary care. 
5.1 Introduction 
Cardiovascular diseases (CVD) are the leading cause of death world-wide [1] and type 2 
diabetes mellitus (T2D) is an independent risk factor for CVD.  In 2004, heart disease 
was responsible for 68% and stroke was responsible for 16% of all deaths in patients 
diagnosed with T2D in the United States [2].  Central obesity, high blood pressure (BP), 
dysglycemia and dyslipidemia are some of the major cardiometabolic risk factors 
implicated in the development of CVD and T2D [3,4].  Clustering of these risk factors, 
termed metabolic syndrome (MetS) increases the risk of disease progression more in 
combination than additive risk [3,4].  
Mechanisms associated with the progression from MetS to T2D and CVD are poorly 
understood.  Autonomic dysfunction has been hypothesized to be an important 
component of CVD progression [5,6].  Abnormal cardiac autonomic function, as 
indicated by low heart rate variability (HRV), is associated with increased all-cause and 
cardiovascular mortality in post-myocardial infarction patients [7,8] and with the 
development of T2D in a general population [9,10].  Furthermore, individuals with T2D 
and low HRV were more likely to develop CVD than those with normal HRV values 
[11,12].  Low HRV is also characteristic of MetS populations [13].  Autonomic 
dysfunction is consistently reported in females with MetS, while findings are more 
controversial in males [14-16].  A systematic review showed that MetS risk factors are 
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associated with different HRV parameters and suggested that impaired autonomic 
function, or low HRV, may be an important mechanism in the continuum of CV risk [17]. 
However, to date studies are cross-sectional and associations between longitudinal 
changes in MetS and HRV have not been examined.   
Physical activity is recommended as a first line treatment for MetS [3,4].  Lifestyle 
changes have proved to reduce disease progression [18,19] and long-term follow-up has 
determined that lifestyle changes are more effective than metformin in reducing the 
incidence of T2D [20].  Exercise also improves HRV in the general population [21,22] 
and in T2D [23,24].  These concomitant improvements in MetS risk factors and HRV in 
response to exercise suggest that they may be linked mechanistically.  However, 
longitudinal associations have not been examined.  
Despite the well-known health benefits of physical activity, accelerometer data has 
shown that 85% of Canadians [25] and 90% of Americans [26] do not meet national 
physical activity guidelines.  Electronic health (eHealth) is a relatively new field in which 
electronic medium is used to support health.  While studies are still in their infancy some 
successes have been noted [27].  Mobile health (mHealth) is a branch of eHealth that has 
the potential to be better than general eHealth interventions because of the portability.  
Eighty-five percent of the American population owns a mobile phone, and in this group 
Smartphone ownership has risen from 33% in May 2011 to 53% in November 2012 [28]. 
With the quickly growing number of smartphone users, mHealth interventions allow for 
the potential to act as a trigger for behaviour or to provide information at the time that it 
is needed.  We recently showed that a mHealth supported exercise intervention increased 
activity and improved MetS risk factors in a rural population [29].  Additionally, 
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participants found the technology acceptable and motivational [30].  Despite a small 
sample size and short follow-up period, improvements in 24h HRV were apparent 
(unpublished data; Chapter 4).  However, due to the single group design of the pilot 
study, it is unknown whether the mHealth component had added benefit compared to the 
exercise intervention alone.   
The purpose of this randomized controlled trial was two-fold: 1) to examine associations 
between longitudinal changes in HRV parameters and MetS components; and 2) to 
isolate the mHealth component by comparing the effects of an exercise intervention 
supported by mHealth technology to exercise prescription alone.  We hypothesized that 
changes in MetS components would be associated with changes in HRV parameters and 
that the mHealth supported group would have greater improvements in MetS risk factors 
and HRV than the control group. 
5.2 Methods  
This study was part of a 12-month randomized controlled trial, in which 149 participants 
from rural Southwestern Ontario were block randomized to either the exercise 
prescription plus mHealth technology intervention group (EX+T; n=75) or the exercise 
prescription only active control group (EX-C; n=74).  This paper reports interim results at 
24 weeks.  At screening, participants were required to have a minimum of two of five 
MetS risk factors according to National Cholesterol Education Program – Adult 
Treatment Panel III (ATPIII) criteria – waist circumference ≥ 88cm (women) or 102cm 
(men); systolic blood pressure (SBP) ≥ 135mmHg and/or diastolic BP (DBP) ≥ 85 
mmHg; fasting plasma glucose (FPG) ≥ 6.1 mmol/L; fasting triglycerides (TG) ≥ 1.7 
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mmol/L; fasting high density lipoprotein cholesterol (HD) ≤ 1.29 mmol/L (women) or 
1.02 mmol/L (men) [31].  Exclusion criteria were systolic blood pressure (SBP) > 180 
mmHg and/or diastolic blood pressure > 110mmHg; type 1 diabetes; history of 
myocardial infarction, angioplasty, coronary artery bypass or cerebrovascular 
ischemia/stroke; symptomatic congestive heart failure; atrial flutter; unstable angina; 
unstable pulmonary disease; use of medications known to affect heart rate (HR); second 
or third degree heart block; history of alcoholism, drug abuse or other emotional 
cognitive or psychiatric problems; pacemaker; unstable metabolic disease and orthopedic 
or rheumatologic problems that could impair the ability to exercise.  The study was 
approved by the University of Western Ontario research ethics board (#15828) and 
participants provided informed consent to participate. 
Participants reported to the Gateway Rural Health Research Institute (Seaforth, Ontario) 
at baseline (V0), 12 weeks (V1) and 24 weeks (V2).  Automated BP was measured in the 
supine position (BPTru™, VSM MedTech Ltd., Coquitlam, BC) and the average of the 
last two of three measures was used to determine clinic BP.  WC was measured as the 
midpoint between the lower rib and iliac crest (cm) [32].  Blood was drawn and sent to a 
central laboratory for measurement of FPG, TG and HDL.   
Autonomic testing 
Following a light, standardized snack, participants were instrumented for collection of a 
lead II ECG (Colin Pilot 9200, Colin Medical Instruments, San Antonio, Texas) and 
respiratory rate by belt transducer (Pneumotrace II, ADInstruments, Colorado Springs, 
Colorado) secured around the thorax. Data were collected during ten minutes of supine 
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rest.  External stimuli, such as light and noise were controlled to ensure signal stability.  
Participants were instructed to remain still and awake.  All measures were sampled at 
1000Hz, input into a data acquisition board (PowerLab ML795, ADInstruments) for 
analog-to-digital signal conversion with LabChart7Pro software (ADInstruments) and 
stored for offline analysis.   
Exercise testing and prescription 
Fitness (VO2max; ml/kg/min) was estimated with the Step Test Exercise Prescription 
(STEP™) tool, which has been validated in adults aged 18-85y [33,34].  The full protocol 
has been published elsewhere [35].  Briefly, participants were instructed to step up and 
down a set of two steps twenty times at a comfortable pace.  Heart rate (HR) was 
measured immediately following the test by palpation of the radial artery and age, 
weight, sex, time to complete test and post-test HR were used to calculate predicted 
VO2max (Appendix 1).  Fitness was classified by age, sex and VO2max  as poor, fair, good 
or excellent.  A tailored exercise program including target HR based on fitness level 
[poor =70% maximum age-predicted HR (HRmax); fair = 75% HRmax; good = 80% HRmax; 
excellent = 85% HRmax] was prescribed based on the results of STEP™ and an exercise 
specialist helped participants set SMART (specific, measurable, attainable, realistic, 
timed) goals.  For EX+T, goals included increasing steps per day with pedometer 
monitoring, with the overall goal of achieving 10,000 steps per day.  The exercise 
program and goals were updated at each visit.   
Mobile Health Intervention 
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Participants received a smartphone (Blackberry Curve 8300 or 8530, Research in Motion, 
Waterloo, ON) equipped with health monitoring application (Healthanywhere, BioSign, 
Markham, ON), a Bluetooth enabled BP monitor (A & D Medical, UA-767PBT, San 
Jose, CA), a glucometer (Lifescan One Touch Ultra2™, Milpitas, CA) with Bluetooth 
adapter (Polymap Wireless, PWR-08-03, Tucson, AZ) and a pedometer (Omron, HJ-150, 
Kyoto, Japan).  A group training session (approximately two-hour duration) was 
delivered at V0, during which participants were instructed on proper use of devices and 
techniques to get proper measurements.  FPG and BP measures were to be submitted 
thrice weekly upon waking and pedometer steps were to be input nightly.  Details of data 
transfer, biometric thresholds for alerts and database security are reported elsewhere [30]. 
Heart rate variability analysis 
R-R intervals (RRI) were extracted from continuous ECG recordings for analysis with 
HRV software (Hearts v7, Heart Signal Co., Oulu, Finland). The HR time series was 
edited by a single investigator.  All ECG signals were manually scanned for ectopic or 
non-sinus beats, which were deleted from the time series.  Datasets were excluded from 
analysis when more than 10% of beats were edited.  Time domain HRV analyses 
included HR, SDNN and the root square mean of successive differences (RMSSD).  The 
HRV spectrum was computed with the non-parametric fast Fourier transform method.  
Low frequency (LF: 0.04-0.15Hz), high frequency (HF: 0.15-0.4Hz), LF/HF and total 
power (TP: 0.003-0.4Hz) were examined [36].  These measures are repeatable over short- 
and long-term [37].  Each RRI was plotted against the following one to create a Poincaré 
plot.  The standard deviation of the width (SD1) and length (SD2) were calculated 
[38,39].  The detrended fluctuation analysis method was used to examine fractal 
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characteristics of heart rate fluctuations [40].  The root-mean square fluctuations of 
integrated and detrended data were measured in observation windows and then plotted 
against the size of the window on a log-log scale.  The short-term scaling exponent (α1) 
was calculated from the slope of the line (from 4-11 beats) [41].   
Statistical Analysis 
Baseline characteristics were compared between groups with unpaired t-tests for outcome 
measures with normal distribution or a two sample Wilcoxon test for outcome measures 
that were not normally distributed.  Analysis of covariance (ANCOVA) was used to 
examine differences in mean change between EX+T and EX-C for MetS risk factors, 
fitness, HOMA-IR and HRV parameters with sex and baseline values as covariates.  Age 
was also included as a covariate for HRV parameters.  Paired t-tests were used to 
examine changes from V0 to V2 for the whole population when there were no differences 
between groups for mean change, or for EX+T and EX-C separately when differences 
were shown by ANCOVA.  Multiple linear regression models were used to investigate 
how changes in MetS components predicted changes in HRV, while adjusting for other 
variables and baseline values.  An a priori decision was made to force age, sex, group 
and VO2max into the equation to adjust for potential confounders.  Backwards elimination 
was used to create the most appropriate model.  All MetS components were originally 
included in the model and the least important was serially excluded using the criteria 
p<0.1.  This strategy sought to identify a parsimonious set of predictors for the outcome 
of interest.  Upon completion of the initial model, diagnostics were run to test for 
influential observations and outliers were removed when necessary.  All results are 
shown as mean ± standard deviation for normally distributed data, median (interquartile 
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range; IQR) for non-parametric data, and multiple linear regression results are presented 
as estimate (95% confidence interval; CI), unless otherwise specified.  R statistical 
software was used for analysis [42].   
5.3 Results 
Participant Characteristics 
After removal of incomplete data, 116 participants (62 EX+T; 54 EX-C) were included in 
the final analysis (Table 5.1).  FPG (p=0.008) and HOMA-IR (p=0.010) were higher in 
EX+T compared to EX-C, but groups were otherwise similar. 
Longitudinal changes in metabolic syndrome risk factors and heart rate variability 
parameters 
There was no difference between groups in mean change for any MetS risk factor, 
VO2max or HOMA-IR (p>0.05).  Figure 5.1 shows changes in MetS risk factors over time.  
WC (V0: 103.5±13.2 cm; V2: 99.7±12.4 cm; p<0.001), SBP (V0: 141±19 mmHg; V2: 
131±15 mmHg; p<0.001) and DBP (V0: 86±11 mmHg; V2: 81±9 mmHg; p<0.001) were 
reduced over time across the whole population with no differences between groups 
(p>0.05).  There were no changes in FPG (V0: 5.0(0.8) mmol/L; V2: 5.0(0.6) mmol/L), 
TG (V0: 1.36 (0.96) mmol/L; V2: 1.32(0.91) mmol/L), HDL (V0: 1.40 (0.53) mmol/L; 
V2: 1.38(0.51) mmol/L)  or HOMA-IR (V0: 1.63(1.75); V2: 1.54(2.09)) over time 
(p>0.05).  VO2max increased in the whole population with no differences between 
treatment groups (V0: 30.77±6.22 ml/kg/min; V2: 32.81±6.24 ml/kg/min; p<0.001).  
RMSSD, lnHF and SD1 were reduced at V2 compared to V0 (p=0.048, 0.032 and 0.049,  
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Table 5.1:  Participant characteristics 
 Exercise + Technology Exercise Only p 
N 62 54  
Age (y) 58.0 (14.0) 59.5 (11.8) 0.482 
WC (cm) 105.2±12.6 101.7±13.8 0.151 
SBP (mmHg) 141±20 142±19 0.926 
DBP (mmHg) 86±13 87±10 0.690 
FPG (mmol/L) 5.1 (0.9) 4.9 (0.5) 0.013* 
TG (mmol/L) 1.42(0.76) 1.31 (1.05) 0.791 
HDL (mmol/L) 1.34 (0.57) 1.45 (0.47) 0.312 
HOMA-IR 1.90 (1.66) 1.37 (1.01) 0.010* 
VO2max (ml/kg/min) 30.0±6.3 31.4±6.3 0.236 
DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density 
lipoprotein cholesterol; HOMA-IR, insulin resistance; SBP, systolic blood pressure; TG, 
triglycerides; VO2max, maximal oxygen uptake; WC, waist circumference. 
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Figure 5.1:  Changes in metabolic syndrome risk factors over time. A) waist 
circumference, systolic and diastolic blood pressure; B) fasting plasma glucose, 
triglycerides and high density lipoprotein cholesterol; at V0 (black bar) and V2 
(white bar). * p<0.05 
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respectively), but there were no other significant changes in HRV parameters over time 
(Table 5.2).  
Associations between changes in metabolic syndrome risk factors and heart rate 
variability 
Multiple linear regression (Table 5.3) showed that the change in HR and SDNN were 
associated with the change in WC (p=0.033) and FPG (p=0.048), respectively.  The 
change in α1 was associated with the change in SBP (p=0.045) and TG was included in 
the model to improve the fit (p=0.066).  The change in MetS risk factors over the 
intervention period were not associated with the change in HRV parameters RMSSD, 
lnLF, lnHF, lnTP, LF/HF or SD1. 
5.4 Discussion 
The main findings of this study were that: 1) WC, SBP and FPG were the only MetS 
components that independently predicted changes in HRV, and only changes in HR, 
SDNN and α1 were associated with MetS component changes; 2) RMSSD, lnHF and SD1 
were reduced following the intervention period with no other changes in HRV; and 3) 
WC, SBP and DBP were reduced following the 24-week intervention with no change in 
other MetS risk factors and no differences between treatment groups. 
Previous studies have examined associations between HRV parameters and MetS risk 
factors in cross-sectional studies [13-16].  To our knowledge, this was the first study to 
examine these associations over a longitudinal intervention period.  Interestingly, 
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Table 5.2: Changes in heart rate variability from baseline to 24 weeks 
 V0 V2 p 
HR (bpm) 63±9 62±8 0.099 
SDNN (ms) 45(30) 42(23) 0.371 
RMSSD (ms) 1114(1966) 753(1449) 0.048* 
lnLF (ms2) 6.03±1.07 5.93±0.84 0.270 
lnHF (ms2) 5.87±1.39 5.60±1.00 0.032* 
lnTP (ms2) 7.48±0.90 7.37±7.39 0.183 
LF/HF 1.15(1.77) 1.51(1.86) 0.169 
SD1 (ms) 23.7(20.3) 19.4(17.7) 0.049* 
α1 1.01±0.33 1.06±0.26 0.112 
α1, short-term scaling exponent; HF, high frequency power; HR, heart rate; LF low 
frequency power; RMSSD, root mean square of successive differences; SD1, width of the 
Poincaré plot; SDNN, standard deviation of normal-to-normal intervals; TP, total power. 
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Table 5.3: Multiple linear regression examining contribution of change in metabolic 
syndrome risk factors to change in heart rate variability parameters.  
 Estimate 95% CI p F-statistic Adjusted R2 
HR 
     WC 
 
0.129 
 
(0.011, 0.247) 
 
0.033* 
5.786 0.224 
SDNN 
     FPG 
 
-3.332 
 
(-6.629, -0.035) 
 
0.048* 
6.075 0.2314 
α1 
     SBP 
     TG 
 
-0.003 
-0.038 
 
(-0.006, -7.0x10-5) 
(-0.078, 2.5x10-3) 
 
0.045* 
0.066 
16.58 0.541 
α1, short-term scaling exponent; FPG, fasting plasma glucose; HR, heart rate; SBP, 
systolic blood pressure; SDNN, standard deviation of normal to normal intervals; TG, 
triglycerides; WC, waist circumference. 
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 associations with changes in HRV and MetS risk factors overtime were different than 
cross-sectional associations.  Changes in the HRV parameters that are traditionally 
considered to be reflective of vagal activity during supine rest (RMSSD, HF, SD1) were 
not independently predicted by change in MetS risk factors, though in cross-sectional 
analyses, these HRV parameters were independently predicted by WC and FPG (chapter 
3).  On the other hand, parameters with sympathetic influence, reflecting overall 
variability, or fractal complexity were associated with changes in MetS risk factors.  The 
change in HR was independently predicted by changes in WC.  In the Diabetes 
Prevention Program, a higher baseline HR was related to incident diabetes [10].  
Preliminary results have suggested that HR may be reflective of sympathetic activity in 
MetS population [43].  Abdominal obesity is often considered a cornerstone of MetS, and 
in fact is a mandatory risk factor in some MetS definitions [32].  Visceral fat is 
hypothesized to be one of the major contributors to insulin resistance [44], which is 
associated with sympathetic hyperactivity [45-47].  Together, these findings suggest that 
improvements in abdominal obesity may be responsible for normalization of sympathetic 
activity seen as a reduction in HR.   
Importantly the change in SDNN was independently predicted by the change in FPG.  A 
longitudinal study showed that in T2D, those within the lowest quartile of two-minute 
SDNN had approximately double the risk of incident coronary heart disease and incident 
myocardial infarction compared to those in the higher three quartiles [11].  These 
findings suggest that improvements in FPG would increase SDNN and therefore, 
potentially reduce the risk of cardiovascular complications of T2D.  However, the 
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increased risk with reduced SDNN was not apparent in participants without T2D [11] and 
reduced SDNN did not predict the development of T2D in a general population [9].   
In this study, changes in α1 were independently predicted by changes in SBP, with each 
mmHg decrease in SBP predicting a small, but significant increase in α1.  The breakdown 
of fractal complexity (seen as alterations of α1) are associated with either lack of 
variability or with complete randomness [41,49], both of which are seen in patients with 
advanced disease such as congestive heart failure, complex arrhythmias or post-
myocardial infarction patients [50].  Reductions in SBP are known to lower 
cardiovascular risk and these findings suggest, that mechanistically, it may be related to 
fractal behaviour of heart rate dynamics. 
Previous studies have shown that exercise improves HRV [21-24].  This is contrary to 
our results which showed that RMSSD, lnHF and SD1 – parameters considered primarily 
reflective of vagal activity under resting conditions – were reduced over the 24-week 
intervention period rather than increased as expected.  However, in some studies, resting 
HRV was not a sensitive enough measure to detect subtle changes in autonomic function.  
Improvements in autonomic function were detected when HRV was measured during 
recovery from moderate intensity exercise [51] or when reflex autonomic control was 
assessed by baroreflex sensitivity [52].  Additionally, one study examined the dose 
response of exercise for changes in HRV.  Completing approximately 50% of national 
recommendations for exercise resulted in improvements in lnLF, lnVLF and lnTP, while 
meeting national recommendations or exceeding them by 50% improved all time and 
frequency domain HRV parameters examined except for HR and LF/HF [53].  Although 
the participants in the current study were prescribed exercise according to national 
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physical activity guidelines, it cannot be concluded that targets were met since exercise 
was unsupervised.  Therefore, changes may not have been seen in this study if 
recommendations were not followed appropriately.   
Exercise also has benefits for MetS population and is the recommended first-line 
treatment for cardiometabolic risk factors [4].  A recent meta-analysis of exercise effects 
on cardiovascular risk factors in T2D showed that aerobic exercise resulted in reduced 
glycated hemoglobin (a measure of glycemic control over the past 12 weeks), SBP and 
TG, with no changes in HDL or WC [54].  This paper did not examine changes in either 
FPG or DBP.  Our intervention may have failed to change FPG as the mean was within 
healthy limits and only seven individuals (6%) had a FPG > 6.1mmol/L to qualify as a 
risk factor.  Similarly, the mean TG was also within a healthy range.  On the other hand, 
SBP and DBP were elevated outside normal ranges (>135/85) at V0 and therefore had 
greatest potential for improvement.   
This intervention used the STEP™ tool for exercise counseling, which has proved to 
effectively increase fitness and improve MetS risk factors [35].  Indeed, the 7% and 6% 
reductions in SBP and DBP, respectively, are similar to changes that have been seen with 
other interventions using STEP™ [35] and are in line with changes in BP with exercise in 
hypertensive populations [55].  The 7% increase in VO2max was lower than other studies 
employing the STEP™ intervention [35], which suggests that exercise goals may not 
have been met and may explain in part lack of change of some MetS risk factors.   
Contrary to our hypothesis, there were no differences between EX+T and EX-C.  A six-
month lifestyle intervention including health monitoring, counseling, education, exercise 
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and diet improved WC to a greater extent in the intervention compared to the control 
group, with no differences in other MetS risk factors [56].  The addition of diet to the 
intervention is likely responsible for the improvements in WC.  Another study examined 
an eHealth-based intervention which included monitoring of BP, steps and body fat; a 
four-week education module; telephone counseling; and text and email messages for six 
months [57].  After six months, all MetS risk factors had improved except for HDL; 
however, this was a pilot study, so a control group was not included [57].   
Two systematic reviews have had conflicting results regarding the effectiveness of 
eHealth on physical activity and weight loss [27,58].  A review of eHealth interventions 
showed that only three of thirteen studies showed improvements in physical activity [27], 
while a review of SMS studies showed that three of three studies successfully increased 
physical activity and eleven of fourteen studies resulted in weight loss [58].  mHealth 
may be more effective than other types of eHealth interventions due to their portability 
and convenience and their ability to trigger behaviours or provide support at the 
appropriate time.  Since the participants in our intervention primarily used their 
smartphone as a data portal for submitting measures, the full potential of the smartphone-
based intervention may not have been realized.  Telemonitoring of blood pressure [59] 
and self-management of blood glucose via mobile phone [60] is more effective than usual 
care.  This mHealth intervention may not have had as much success as it was essentially a 
self-management protocol with little interaction between the research team and 
participants. Other mHealth interventions have used text messaging for feedback and 
encouragement throughout the study.  While participants attended an intensive training 
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session, more regular contact (either automated or personalized) may have increased the 
success of the intervention.  
This study was limited to a small, rural population presenting with MetS risk factors; 
therefore, results may not be generalizable to urban or other populations.  Since the 
exercise was unsupervised and pedometer steps were self-reported, the actual amount of 
exercise completed cannot be confirmed.  Additionally, since dietary changes were not 
tracked, some participants may have chosen to change their diet, which may have 
contributed to positive changes in MetS risk factors and HRV, and these would not be 
accounted for in the analysis.  Although there is some evidence that HR may be 
indicative of sympathetic activity in MetS [43], direct measures such as measurement of 
muscle sympathetic nerve activity would have been ideal.  However, these measures are 
expensive, time consuming and impractical for large populations. 
In conclusion, this six-month intervention showed that changes in HR, SDNN and α1 
were associated with changes in MetS risk factors, but HRV parameters more specifically 
indicating vagal activity were not.  These associations were seen despite the fact that 
HRV was not improved by the intervention and the only MetS risk factors that were 
improved were WC, SBP and DBP.   
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CHAPTER 6 
Thesis Summary, Discussion and Conclusions 
6.1 Summary of the Thesis 
6.1.1 Associations between heart rate variability and metabolic syndrome risk 
factors 
The purpose of this thesis was to examine relationships between heart rate variability 
(HRV) and metabolic syndrome (MetS) risk factors.  Chapter 1 was a review of the 
literature, which discussed cardiometabolic risk and proposed that based on prognostic 
value and relationships with MetS risk factors, HRV may have potential as a novel 
cardiometabolic risk factor.  Studies examining associations between HRV and MetS 
were identified and synthesis of results was recommended. 
Chapter 2 was a systematic review with the purpose of describing studies to date 
examining the associations between MetS and HRV.  This paper showed that HRV was 
reduced in women with MetS, though findings were inconsistent in men.  This paper also 
noted that most HRV indices were not reduced until three or more MetS components 
were present – only 24-hour short-term scaling exponent (α1) and five-minute standard 
deviation of normal-to-normal intervals (SDNN) were altered with less than three 
components.  Associations between individual MetS risk factors and HRV parameters 
were also reviewed in this paper.  It was concluded that associations between MetS risk 
factors and HRV parameters varied depending on the population and that greater 
consistency in methodology was needed.  Additionally, it was suggested that associations 
with insulin resistance should be further investigated.  
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Chapter 3 was a cross-sectional examination of the associations between HRV, MetS risk 
factors and insulin resistance.  HRV was not lower in MetS compared to those without 
MetS in men.  In women, however, HRV was generally lower in MetS, but there were no 
differences in HRV parameters reflective of vagal activity.  HRV parameters reflective of 
parasympathetic activity were independently predicted by waist circumference (WC) and 
fasting plasma glucose (FPG), while those reflecting overall variation were predicted by 
triglycerides (TG) and high density lipoprotein cholesterol (HDL).  Insulin resistance was 
only associated with heart rate (HR) 
Chapter 5 was a 24-week intervention study, which showed that the changes in MetS risk 
factors were generally not associated with changes in HRV parameters.  The change in 
WC was associated with the change in HR; the change in SDNN was associated with the 
change in FPG; and the change in α1 was associated with the change in systolic blood 
pressure (SBP).   
6.1.2 Exercise intervention as a cardiometabolic risk modifier 
Chapter 1 also reviewed the role of exercise as a cardiometabolic risk modifier.  
Generally, exercise and physical activity have proved to reduce WC and blood pressure 
(BP) and increase HDL in MetS [1].  Studies examining the effects of exercise on HRV 
are equivocal with some interventions improving HRV [2-5], while others had no effects 
[6].  Exercise prescription may be an important factor.  Evidence suggests that frequency 
of training may be important to effectively modify HRV, while intensity and duration 
may be less important.   
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Novel interventions for improving exercise uptake were also examined.  The Step Test 
and Exercise Prescription (STEP) test has effectively modified both traditional and novel 
cardiometabolic risk factors [7] and was the only exercise counseling intervention in 
primary care that improved fitness [8].  Mobile health (mHealth) interventions were also 
reviewed, which showed promise as a tool for self-management for weight loss, physical 
activity and diabetes management.  It was suggested that a unique intervention combining 
exercise prescription and self-management with mHealth technology had potential as an 
intervention to reduce cardiometabolic risk. 
Chapter 4 was a pilot study to determine the feasibility and utility of an intervention 
utilizing the STEP intervention supported by self-management with a mHealth 
application.  Twenty-four participants with at least two MetS risk factors volunteered for 
this study, which proved that the intervention was feasible and acceptable in a rural 
population.  Despite the short intervention length (eight weeks), WC, DBP and total 
cholesterol were reduced and fitness and physical activity were increased [9,10].  The 
high (HF) and low frequency (LF) powers of HRV in normalized units were altered 
following the intervention and DBP was correlated with LF/HF, but there were no other 
changes in HRV or correlations between HRV and MetS risk factors.  Despite these 
promising changes, it remained unclear whether the mHealth intervention was of any 
added benefit compared to the exercise prescription alone.   
Chapter 5 was a randomized controlled trial comparing the effects of a 24 week mHealth 
supported exercise intervention to standard of care exercise advice with STEP.  
Participants with two or more MetS risk factors were randomly allocated to either an 
intervention (n=75) or active control (n=74) group.  The intervention group received the 
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mHealth supported exercise intervention described in chapter 4, while the control group 
received only the exercise testing and prescription. Over the 24-week intervention period, 
there were no differences in changes between the intervention and control groups.  WC, 
SBP and DBP were reduced with no changes in other MetS risk factors.  Root mean 
square of successive differences (RMSSD), lnHF and Poincaré plot width (SD1) were 
reduced over the intervention period with no changes in other HRV parameters.   
6.2 Discussion and Future Directions 
Recent reviews discussed cardiac autonomic function in the progression of type 2 
diabetes mellitus (T2D) [11,12].  The reviews hypothesized that vagal modulation is 
reduced initially at the onset of disease and is in fact the first sign of autonomic 
dysfunction.  The results of this thesis showed that in a population with or without MetS, 
there were no differences in vagal indices RMSSD, lnHF or SD1. This suggests that 
either vagal indices are reduced before even development of one risk factor and therefore, 
no differences are apparent between groups, or that vagal changes occur later in the 
progression of disease.  Unfortunately, since this thesis did not include a population of 
healthy individuals with zero MetS risk factors, this cannot be determined.  Over a 24-
week intervention that improved BP, vagal HRV indices RMSSD, lnHF and SD1 were 
reduced.  There were no mean changes in MetS status, so the reduction in vagal HRV 
indices over time may have been indicative of disease progression despite improvements 
in some MetS components (Chapter 5).  Additionally, WC and FPG were primarily 
associated with all three vagal indices (Chapter 3), suggesting that these two MetS 
components may be important in the treatment of cardiometabolic risk.  The Diabetes 
Prevention Program Outcomes Study showed that the risk of developing T2D was 56% 
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lower for participants in whom FPG was reduced to normoglycemia compared to those 
with persistently elevated FPG [13].  Reduced SDNN has been shown to be a predictor of 
mortality and changes in SDNN were related to changes in FPG (Chapter 5), though in a 
cross-sectional examination SDNN was predicted by lipid profiles (Chapter 3).  Future 
studies should examine the importance of cross-sectional versus longitudinal change 
associations between HRV parameters and MetS risk factors. 
Although parasympathetic dysfunction has been implicated as the first sign of disease, 
the results of this thesis suggest that alterations in HRV associated with overall variation, 
complexity and perhaps sympathetic activity may be a better indicator of MetS.  Vagal 
indices may already be reduced with the presence of one risk factor, making it a poor 
indicator of disease progression.  However, in cross-sectional studies, only SDNN and α1 
were reduced when less than three MetS risk factors were present (Chapter 2).  Evidence 
suggests that increased sympathetic activity may be present in MetS and that it may, in 
fact be mechanistically linked directly to insulin resistance and the progression of disease 
[14-16].  The studies included in this thesis were not designed to measure sympathetic 
activity directly.  Other studies have shown that norepinephrine spillover and muscle 
sympathetic nerve activity are increased in MetS [15,16].  The current study showed that 
heart rate was increased in MetS compared to those without and preliminary findings 
have suggested that heart rate may be a surrogate measure of sympathetic activity in 
MetS [14].     
Exercise interventions have shown promise in improving MetS and HRV.  The DaTA 
study (chapter 4) showed some improvements in MetS risk factors and 24h HRV 
parameters over eight weeks, but over a 24-week intervention period (chapter 5) some 
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MetS risk factors were improved, but 5min resting HRV parameters reflective of vagal 
activity were actually lower instead of higher as expected.  VO2max was increased 18% in 
chapter 4, but only 7% in chapter 5.  These differences in fitness improvements may be 
responsible for inconsistent findings.  Aerobic fitness is protective against mortality [17] 
and improvements in autonomic function accompanying increased fitness may play a 
role. 
 Exercise is known to have positive health benefits beyond those directly associated with 
HRV.  Intensive lifestyle intervention programs reduced the risk of developing T2D in 
prediabetes and changes were maintained over a long-term follow-up, though there was a 
strong relationship between reduced disease progression and continuance of lifestyle 
intervention behaviours [18].  These finding highlight the importance of post-program 
support for long-term maintenance.  Knowledge translation activities are important to 
translate research protocols into useable programs.   
mHealth applications have the potential to reach a broad population and provide a 
convenient and effective medium for delivery of interventions.  Although there is a 
growing body of literature in this field, studies to date are heterogeneous with respect to 
study population, intervention delivery and reported outcomes.  With rapid technological 
developments it is difficult to plan and implement robust clinical mobile health trials 
within the current research environment before technology is outdated.  Many published 
mHealth interventions do not use the technology to its full potential and better results 
may be realized by utilizing as many smartphone features as possible in an intervention.  
Future research should examine published literature to determine the most beneficial use 
of mobile technology for optimal health results.  Smartphone applications are being 
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developed at a fast rate, with many aimed at health and behaviour management.  
However, a review cautioned that few applications are based in theory [19] and that the 
success of mobile health interventions could be maximized by developing evidence-based 
applications specific to population needs.  This will be important if mHealth becomes 
integrated into clinical practice in the future. 
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APPENDIX 1: 
The STEP™ Protocol 
The STEP™ Protocol includes two basic components: the stepping fitness test and an 
exercise prescription. 
Part A: The stepping fitness test 
Begin the stepping fitness test by demonstrating the stepping pattern to patients: stepping 
one foot at a time up both steps and back down again (“up, up, together, down, down, 
together”). Emphasize that only one foot is on the middle step at any one time.  Also 
remind the patient that one step is counted after stepping up to the top step and returning 
back down to the starting position. Instruct the patient to complete 20 consecutive 
stepping cycles at a self-selected normal pace (similar to the pace they would use to 
climb stairs). When the patient is ready to begin, start the timer as their first foot leaves 
the ground. During the test, count each step aloud as they complete it. Offer 
encouragement and watch for signs of fatigue or balance problems (or any signs of 
concern for their safety). Although the individual self-selects the pace to complete the 
stepping test, encourage them to maintain a consistent speed. For example, if they are 
“racing” through it, be sure to encourage the patient to slow down to ensure valid results. 
As the patient performs the last step, be prepared to take their heart rate when they 
complete the test. Take the post-exercise heart rate, palpating radially in a 6 second 
count. The patient can rest while you complete the equation for predicted aerobic 
capacity.  
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Part B: Exercise prescription 
Calculate the patient’s target training heart rate, using 70-85% of their age-predicted 
maximal heart rate as a target.  Generally, individuals with lower aerobic fitness levels 
should be advised to stay at the lower end of their target HR zone (70%). Those with high 
fitness levels should be encouraged to aim for the higher range (80-85%) depending on 
their current physical activity/exercise regimes and their limitations. 
Complete the exercise prescription note for the patient, including: date of test, predicted 
VO2max, target training heart rate (including beats per minute and beats in 10 seconds), 
and frequency of activity. (Appendix Figure 1) It is helpful to provide patients with a 
copy of Canadian physical activity guidelines during this process, which highlight that 
Canadian adults should aim for at least 150 minutes of moderate- to vigorous-intensity 
physical activity each week and that this can be accumulated in a minimum of 10-minute 
bouts (CSEP, 2011). During the exercise prescription process, it can be helpful to 
describe the term VO2max as well as training heart rate to patients. The definitions below 
have been applied for this purpose. 
 VO2max is a measure of your cardiorespiratory (or aerobic) fitness. It is a score 
of how well your heart, lungs, and muscles work together. The higher this number 
is, the more fit you are. You can become more fit by increasing your aerobic 
physical activity. Some examples of aerobic physical activity include walking, 
swimming, or shovelling the driveway. 
 Training Heart Rate – In order to improve your fitness, it is important to check 
your heart rate during physical activity. This training heart rate has been 
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prescribed specifically for you based on your exercise results. The easiest way to 
check your pulse is to count how many times you feel your heart beat in 10 
seconds. 
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Appendix Figure 1: STEP Worksheet 
 
 
STEP™ Test  
Calculation Worksheet 
Participant Data: 
Sex (male=1, female=2)  
Age (years)  
Weight (kg)  
Time required for STEP test (sec)  
Heart Rate after STEP test (bpm)  
 
Calculations: 
Step Calculation Answer 
1 (1511/time)*weight/heart rate = 
2 ([Ans Step1] *0.124) – (age*0.032) – (sex*0.633) + 3.9 = 
3 ([Ans Step 2] *1000)/weight = 
  VO2max 
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Appendix Figure 2: STEP Exercise Prescription 
  
Date: ____________________ 
 
VO2max: ____________________ ml/kg/min 
 
Classification:       
Needs Improvement      Fair     Good    Excellent 
 
Training Heart Rate:  ____________________ beats/min 
____________________ beats in 10 sec 
 
Type of activity: ________________________________________ 
You should try to be active on most days of the week, and include activities 
that strengthen muscles and bones on 2 days of the the week.  
 
Time: Complete a minimum of 10 minutes per session, to reach a total of at 
least 150 minutes per week to achieve health benefits. 
 
Interrupt time sitting still every 20 minutes 
  
EXERCISE  PRESCRIPTION 
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